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ABSTRACT OF DISSERTATION

THE EFFECT OF HAPTOGLOBIN PHENOTYPES ON MARKERS OF
NEUROINFLAMMATION IN PATIENTS WITH ANEURYSMAL SUBARACHNOID
HEMORRHAGE
Aneurysmal subarachnoid hemorrhage (aSAH) is a severe form of hemorrhagic
stroke resulting from the spontaneous rupture of an intracranial aneurysm and release of
oxygenated blood into the subarachnoid space. In the United States alone, aSAH occurs
in approximately 30,000 patients each year and occurs, primarily, in otherwise healthy
adults, frequently without warning. Sadly, approximately 40% of patients with aSAH
will die in the first 30 days. Of those who survive, only about 75% will be able to live
semi-independently again and only about 60% will be able to return to work.
Delayed brain injuries (DBI), which may affect up to 70% of aSAH patients, are
an important cause of these devastating outcomes. DBI include delayed cerebral
vasospasm (DCV) and delayed cerebral ischemia (DCI). Despite intensive research,
effective preventative and treatment therapies for DBI have not been identified, in part due
an incomplete understanding of their pathophysiology. Although a number of
mechanisms have been proposed, a strong correlation between DBI and inflammatory
mediators, including selectins, integrins, and proinflammatory cytokines, such as IL-1β,
IL-6, IL-8, TNF-α and MCP-1, has been most frequently observed, suggesting an
important role of inflammation in the development of DBI.
Because intracranial blood is a key feature of aSAH, haptoglobin (Hp) has
emerged as a potential patient-specific modifier of DBI risk. Hp is a naturally occurring
acute phase reactant that binds to free hemoglobin (Hb) molecules to facilitate Hb
metabolism by circulating macrophages. In humans, there are 3 different Hp phenotypes,
Hp1-1, Hp1-2 and Hp2-2. Recent clinical observations suggest that different Hp
phenotypes affect the incidence of DBI after aSAH. While the mechanism for this
observation remains unknown, one potential explanation is that Hp may alter the
neuroinflammatory response, reflected in plasma, CSF, or parenchymal concentrations of
pro-inflammatory cytokines. Macrophage CD163 binds Hp-Hb complexes and a freefloating version of CD163, termed soluble CD163 (sCD163), can also be isolated from
plasma and other body tissues in response to stress and as a result of inflammatory injury.
The relationship between sCD163 and different Hp phenotypes is unknown but sCD163
may also have an important role in modulating DBI risk after aSAH.
The objective of this dissertation, therefore, is to investigate the hypothesize that
the different haptoglobin phenotypes modify the risk of DBI through a differential effect
on sCD163 and inflammatory cytokines. To achieve this objective, three specific aims
were completed and are described in detail in this dissertation. First, a prospectively

collected aSAH biobank was established at the University of Kentucky. This biobank
was necessary to facilitate current and future observational aSAH studies. Second, using
data and patient samples from the established biobank, plasma and CSF concentrations of
3 different neuroinflammatory cytokines (IL-1β, IL-6, and TNF-α) were determined at
pre-specified time points and compared against Hp phenotype, clinical outcome, and DBI
diagnoses. Finally, using data and patient samples from the established biobank, plasma
and CSF concentrations of sCD163 was determined at pre-specified time points and were
also compared against Hp phenotype, clinical outcome, and DBI diagnoses.
The proposed biobank successfully recruited 25 patients over a 2-year period. Of
these patients, 3 (12%) were Hp1-1 phenotype, 14 (56%) were Hp1-2 phenotype, and 8
(32%) were Hp2-2 phenotype. There were no statistically significant differences in
plasma or CSF concentrations of any of the measured cytokines at any time point when
subjects were compared by their DCV status, DCI status, Hp phenotype, Hp class, or a
combination of Hp class and DCV or DCI. While there were significant differences in
plasma sCD163 concentration when subjects were compared by a combination of Hp class
and DCV, there were no other statistically significant differences in plasma or CSF
concentration of sCD163 at any time point when subjects were compared by their DCV
status, DCI status, Hp phenotype, Hp class, or a combination of Hp class and DCV or
DCI. These findings are most likely related to the relatively small number of patients
included in these analyses. Future studies should include more patients to better evaluate
the roles that the different Hp phenotypes play in the development of DBI after aSAH.
KEYWORDS: Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Vasospasm,
Delayed Cerebral Ischemia, Haptoglobin, Neuroinflammation
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CHAPTER 1: INTRODUCTION AND LITERAURE REVIEW
1.1 Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is a severe form of hemorrhagic
stroke resulting from the sudden, spontaneous rupture of an intracranial arterial
aneurysm. aSAH results in significant morbidity, disability, and mortality through
combined effects of acute brain injuries and delayed brain injuries (DBI). Haptoglobin
(Hp), a naturally-occurring protein that binds free hemoglobin exists in multiple forms
due to chemical differences in hereditary phenotypes. Recently, different Hp phenotypes
have been correlated to different risks of DBI in patients with aSAH. Although various
pathophysiologic models have been proposed to explain the development of DBI, none
have successfully incorporated the observed differences in DBI between patients with
different Hp phenotypes. I, therefore, hypothesize that the different haptoglobin
phenotypes modify the risk of DBI through a differential effect on soluble CD163
(sCD163) or inflammatory cytokines, including Interleukin 1-beta (IL-1β), Interleukin 6
(IL-6) and Tumor Necrosis Factor-alpha (TNF-α). This dissertation describes a series of
projects designed to evaluate this hypothesis.

First, this introductory chapter provides an overview of the key features of aSAH,
describes the importance of delayed brain injuries (DBI) on clinical outcomes after
aSAH, and details the previously-proposed pathophysiologic models of DBI. This
chapter then focuses on haptoglobin (Hp) as a potential modifier in DBI by describing the
Hp molecule and its role in scavenging free hemoglobin (Hb) and details the potential
1

effect that different haptoglobin (Hp) phenotypes have on DBI and clinical outcomes.
This chapter concludes with a discussion of potential mechanisms, including sCD163 and
the inflammatory cytokines that might explain how the different Hp phenotypes affect the
inflammation-mediated model of DBI.

1.2 Overview of Aneurysmal Subarachnoid Hemorrhage
The rupture of a spontaneously-occurring aneurysm and the subsequent
development of aSAH is an unexpected and frequently catastrophic event for patients and
their families. Because most patients do not know that they even have an aneurysm, the
sudden, unexpected consequences of its rupture are even more physically and
emotionally scarring. Aneurysm rupture and aSAH result in a range of clinical
outcomes from minimal neurocognitive impairment to severe, lifelong neurocognitive
disability or death.

1.2.1 Epidemiology
Intracranial aneurysms are relatively common. Based on autopsy studies,
approximately 3% of the world’s population or more than 200 million people will
develop an intracranial aneurysm at some point in their lives.1,2 Fortunately, not all
people with aneurysms develop aSAH and the worldwide incidence of aSAH is only
700,000 cases per year (approximately 1:100,000 people per year).3,4 In the U.S., the
annual incidence of aSAH is approximately 30,000 cases per year.4 Across the globe,
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the incidence of and mortality from aSAH has decreased over the last few decades likely
due to an increase in the detection and treatment of unruptured intracranial aneurysms.5

aSAH appears to occur most commonly in patients aged 35-60 years.6
Hypertension, hypercholesterolemia, current tobacco use, current alcohol use, and female
gender have all been mildly associated with an increased risk of aSAH.2,7-9 In addition,
there is an increased risk of aSAH in patients with a positive family history; however, no
specific genetic link has been documented in these families. A few rare inherited
diseases, such as autosomal-dominant polycystic kidney disease and Ehlers-Danlos
Syndrome, are also associated with an increased risk of aSAH but the genetic or
structural changes that link these diseases to aSAH have not been discovered. 7,10

1.2.2 Clinical outcomes
Although most intracranial aneurysms do not rupture, when they do, the outcome
is frequently disastrous. aSAH is associated with a very high mortality rate.
Approximately 10-15% of aSAH patients die suddenly either immediately at the time of
aneurysm rupture or before hospitalization.11 Of those who do survive to
hospitalization, another 25-30% die during their hospitalization in the first few weeks
after aneurysm rupture.12 Altogether, approximately 40% of aSAH patients die within
the first 30-days.12-14 These deaths represent the combined effects of profound brain
injuries and systemic complications resulting from aSAH.15 Unfortunately, of those
aSAH patients who do survive, a significant percentage of patients have long term
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disability. A recent survey of outcomes found that only 76% of aSAH survivors are ever
able to live semi-independently again and only 60% of aSAH survivors are ever able to
return to some form of work.16

1.2.3 Routine clinical care
For patients who survive, their hospital care can generally be described in three
phases. In the first phase, initial triage evaluates and stabilizes cardiopulmonary
function. This phase occurs in the emergency department at the time they are brought to
the hospital. Endotracheal intubation and initiation of mechanical ventilation may be
needed for patients who do not have adequate neurologic function to maintain a patent
airway or who do not have adequate respiratory effort or function. Once this initial
triage has occurred, an emergent computed tomography (CT) scan of the head is
performed to evaluate the severity of subarachnoid hemorrhage and the extent of
hydrocephalus. aSAH patients with significant hydrocephalus undergo emergent
ventriculostomy and cerebrospinal fluid (CSF) drainage with an extraventricular drain
(EVD). Elevated blood pressure should also be aggressively controlled to reduce the
risk of aneurysm re-rupture. Patients are then transferred to a specialized neuroscience
intensive care unit (NSICU) for additional care.

In the second phase, after the patient has been transferred to a NSICU, the focus
of care turns to early aneurysm obliteration therapy and treatment of early brain injuries
(EBI). Aggressive treatment of elevated blood pressure is continued and aneurysm
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obliteration procedures occur within the first 48 hours after aneurysm rupture to further
reduce the risk of aneurysm re-rupture. When possible, an endovascular approach to
aneurysm obliteration is performed by placement of specialized catheters through the
arterial system into the intracranial arteries and selective placement of thrombogenic coils
inside the aneurysm. These coils induce an intense fibrotic reaction with the aneurysm
that prevents future rupture. If an endovascular approach is not possible, surgical
craniotomy and placement of a vascular clip across the neck of the aneurysm is
performed.

In the third phase, the focus of care shifts to providing routine critical care and
preventative monitoring and treatment of DBI. For most patients, aggressive control of
elevated blood pressure can be loosened at this point. aSAH patients undergo frequent
neurologic monitoring and daily screening for known or suspected DBI, using physical
examination, transcranial Doppler ultrasonography (TCD), and other radiographic and
angiographic modalities, as needed. In addition, since nimodipine therapy has been
shown to improve long term neurologic recovery, it is initiated at hospital admission and
continued through post-bleed day (PBD) 21. If an EVD was placed, it is typically
removed between PBD10 and PBD14, as tolerated by the patient. If the EVD cannot be
safely removed, a permanent ventriculoperitoneal shunt (VPS) is placed for chronic CSF
drainage. When stable, the patient is transferred to a skilled nursing facility or
rehabilitation center for aggressive brain rehabilitation with neurocognitive, as well as,
occupational and physical therapy.

5

1.3 Delayed Brain Injuries after aSAH
Although there are many determinants of clinical outcome after aSAH, by far the
most importance determinants of long-term outcome in aSAH patients are the direct and
indirect injuries that occur to the brain. These brain injuries are categorized as either
early brain injuries (EBI) or delayed brain injuries (DBI), based on their temporal onset
after aneurysm rupture. EBI occur in the first 72 hours after aneurysm rupture and are
caused by increased intracranial pressure, reduced cerebral blood flow or cerebral
perfusion pressure, direct injury to brain parenchyma and associated structures, cytotoxic
cerebral edema formation, or destruction and deterioration of the blood brain barrier.17,18
Current treatment and research approaches for EBI aim to limit the impact on patients
prior to aneurysm rupture, by improving identification of unruptured aneurysms and
developing and employing more prophylactic endovascular and operative approaches to
aneurysm obliteration.

DBI occur more than 72 hours after aneurysm rupture and add significant
additional morbidity and mortality to aSAH patients. The most common DBI are
delayed cerebral vasospasm (DCV), delayed cerebral ischemia (DCI) and delayed
cerebral infarction, each of which will be discussed in more detail below. Reducing the
occurrence and impact of DBI are important targets of current basic, translational, and
clinical research to improve long term survival and recovery after aSAH. DBI, unlike
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most EBI, are potentially modifiable by new hospital-based treatments and therapies and
will be the major focus of the work described in this dissertation.

1.3.1 Delayed cerebral vasospasm
DCV is an important DBI that results in significant morbidity and mortality after
aSAH.19,20 DCV causes spastic narrowing of one or more intracranial arteries and results
in reduced cerebral blood flow in arterial and capillary beds distal to the affected vessels
that, if not rapidly restored, will result in cerebral infarction and permanent neurologic
damage. 21,22 Based on multiple retrospective observational studies, DCV appears to
occur in 30-70% of patients with aSAH, typically, 3-10 days after aneurysm
rupture.20,21,23,24 The amount of blood in the subarachnoid space, determined from
admission CT scan of the head, is the most important risk factor for the development of
DCV.25 Tobacco use, hypertension and left ventricular hypertrophy are also reported
risk factors for DCV.26,27

Because it is not known which patients will develop DCV and on what day it may
occur, all aSAH patients are screened daily for up to 14 days using transcranial Doppler
(TCD) ultrasonography.28,29 TCD utilizes Doppler assessment of reflected sound waves
(ultrasonography) through the cranial bones to evaluate blood flow velocity (BFV) across
target arteries.30 Although many different arteries can be assessed, the middle cerebral
artery (MCA) and the internal carotid artery (ICA) are the most commonly-visualized
vessels.20,21 To differentiate between a focal increase in BFV, as may be seen with DCV,
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and a global increase in BFV, as may be seen in hyperdynamic cardiac disease, the
MCA/ICA ratio (known as the Lindegaard ratio) is used.30,31 DCV is, therefore, defined
by an elevated MCA BFV (flow velocity greater than 120 cm/s) and a Lindegaard ratio ≥
3. Based on a meta-analysis of 5 trials, TCD appears to be most effective as a screening
tool when BFV measurements are either very low, thereby ruling out DCV, or very high,
thereby confirming DCV.32,33 For patients who cannot undergo TCD monitoring or who
have an equivocal diagnosis of DCV based on TCD, computed tomography angiography
(CTA) or magnetic resonance angiography (MRA) may also be utilized as non-invasive
diagnostic modalities.

When aSAH patients have positive TCD, CTA or MRA findings, invasive digital
subtraction angiography (DSA) is considered the gold-standard diagnostic and treatment
modality. Using DSA, highly-trained clinicians identify areas of vasospasm and employ
treatments to restore blood flow. For most patients, there is no clear correlation between
the vasospastic vessel and the vessel affected by aneurysm rupture.34 Once areas of
vasospasm are identified using DSA, targeted treatments, including angioplasty and intraarterial injection of vasodilators, including verapamil, nicardipine, papaverine and
milrinone, are used to restore the spastic vessel’s intraluminal diameter.35 This targeted
vasodilator therapy minimizes the potential side effects, including hypotension, that may
occur from systemic drug administration.35,36 Following targeted treatment procedures,
patients are monitored for additional episodes of DCV that may occur throughout the
vasospasm window. If additional episodes of DCV occur, patients will undergo repeat
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DSA for additional diagnostic and treatment procedures. Despite these aggressive
interventions, patients with DCV may still develop permanent neurologic injury,
disability, or death.

1.3.2 Delayed cerebral ischemia
Delayed cerebral ischemia (DCI) is another important DBI and is also a major
contributor to long-term morbidity and mortality after aSAH. DCI may affect up to 30%
of aSAH patients.19,37 Patients with DCI typically demonstrate an acute, significant
decrease in global or focal neurologic function that is not apparent immediately after
aneurysm rupture and has no direct relationship to the aneurysm obliteration therapy.38
The major risk factors for DCI include poor clinical condition on admission, large
amount of intracranial blood on initial CT scan, and increasing age.39

DCI is distinguished from other potential causes of causes of neurologic
deterioration by a lack of radiologic, encephalographic or laboratory findings at the time
of neurologic deterioration. DCI is treated primarily with therapeutic hypertension and
an aggressive assessment and reversal of potential causes, including DCV.40-42
Therapeutic hypertension may require fluid administration and/or the use of systemic
vasopressor therapy to increase systemic blood pressure and cerebral perfusion
pressure.41 Patients with refractory DCI, despite therapeutic hypertension and resolution
of reversal of potential causes, is associated with worse long-term neurologic outcome
than patients who have aSAH.37
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1.3.3 Delayed cerebral infarction
Delayed cerebral infarction is diagnosed by either new CT or MRI findings
up to 6 weeks after aSAH demonstrating abnormalities consistent with infarction that
were not present on imaging up to 48 hours after aneurysm rupture.38 Because they are
not present on initial imaging, they are not considered to be related to EBI. Delayed
cerebral infarction occurs in up to 20% of aSAH patients.43,44 Both DCV and DCI have
been associated with delayed cerebral infarction, although the relationship between these
DBI remains poorly understood.43-45

1.4 Models of Pathogenesis of Delayed Brain Injury
1.4.1 Cerebral blood flow mediated model of DBI
Despite multiple decades of research, the pathogenesis of DBI after aSAH is still
not well understood. Historically, DBI were believed to occur in a sequential manner
with each of the DBI leading to a more advanced or more severe type of injury as
described in Figure 1.46,47 In this model, aneurysm rupture results in DCV through one
or more currently hypothesized but unproven mechanisms. Unrecognized or untreated
DCV results in reduced blood flow through the spastic vessel with distal brain tissue
malperfusion and DCI. If unresolved, DCI may become delayed cerebral infarction and
result in permanent neurologic injury and disability. Notably, this is similar to the role
that reduced blood flow appears to play in basic models of neurologic injury and cerebral
infarction in acute ischemic stroke. Unfortunately, based on both clinical and
10

experimental reports, this sequence of events appears to be significantly over-simplified
and does not accurately reflect observations from clinical reports.45,48-50
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Figure 1: Sequential Model of DBI Pathogenesis

The sequential model of Delayed Brain Injury (DBI) pathogenesis is a linear progression
of events from aneurysm rupture and subarachnoid hemorrhage to the clinical
consequence of permanent neurologic injury.
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1.4.2 Inflammation-mediated model of DBI
A more complex model of DBI would, perhaps, better describe the interplay
of the various anatomical and biochemical processes that have been associated with DBI
after aSAH as shown in Figure 2.51,52 This model, developed by me from previously
published work, highlights the proposed role that inflammation appears to play in driving
some or all of these anatomical and biochemical processes.53-55 In addition, this model
acknowledges that there may be an as yet unknown trigger and modifiable factors that
connect subarachnoid hemorrhage to the activated inflammatory response.
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Figure 2: Complex Inflammation-Mediated Model of DBI Pathogenesis

The complex inflammation-mediated model of Delayed Brain Injury (DBI) pathogenesis
describes the interplay of processes triggered by an activated inflammatory response that
leads from subarachnoid hemorrhage to permanent neurologic injury.
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In this model, activation of an acute inflammatory response plays a central
role in the development of DBI after aSAH. This activated inflammatory response to
subarachnoid blood or blood products has been hypothesized to directly or indirectly
affect intracranial vascular tone or to activate additional pathways that stimulate
additional anatomic or biochemical processes that lead to DBI.56-58 Clinically, several
observational studies have shown that aSAH patients with DBI have more symptoms of
systemic inflammation (SIRS), including fever, leukocytosis, tachycardia and tachypnea
than do aSAH patients without DBI.59-61 These studies show that patients with DBI have
a clinically significant inflammatory response to the development of DBI.

In addition, observational studies have attempted to define important
inflammatory pathways affecting the development of DBI after aSAH through
assessments of previously described cytokine concentrations in plasma and CSF after
SAH.54,56 Unfortunately, many of these studies have incomplete or conflicting results
because of significant differences in DBI definitions, sampling time points, sampling
procedures, and inflammatory mediator assays.56 Despite these limitations, IL-1β, IL-6
and TNF-α have most consistently demonstrated differences in aSAH patients with and
without DBI.62-66 More detailed models of the activated inflammatory processes in DBI,
using these and other inflammatory cytokines, have not been described.
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1.4.3 Limitations in aSAH models research
Unfortunately, our understanding and ability to test models of DBI
pathogenesis are hampered by the unpredictable nature of aneurysm development and
rupture in human patients. For example, it is not possible or practical to obtain biofluid
or tissue samples in the hours before aneurysm rupture because it is not known when this
will occur. In addition, basic science research in aSAH is limited by the lack of an
animal model that reliably generates intracranial aneurysms and aneurysm rupture.67,68
At current, experimental SAH is produced in otherwise healthy mice by endovascular
puncture of the internal carotid artery or by injection of arterial blood obtained from the
femoral artery into the cisterna magna.67-69 These models result in arterial blood in the
subarachnoid space but may not produce the same anatomic, biochemical and
inflammatory responses observed in human aSAH.67,68

1.5 Anatomic and Biochemical Processes in DBI
As has previously been described, several anatomic and biochemical processes
have been associated with DBI in aSAH. These processes include endothelial cell
damage and dysfunction, altered vascular smooth muscle responsiveness, excitotoxic
neuronal injury, oxidative stress, apoptosis, and spreading depolarizations. It is likely
that aSAH triggers more than 1 of these in individual patients and different phenotypes of
injury may ultimately be caused by the combinations or inter-connectedness of these
processes in their local neurovascular environment.
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1.5.1 Endothelial cell damage and dysfunction
Endothelial cells (EC) line the internal surface of the intracranial vascular
architecture and are responsible for maintaining the blood-brain barrier, for preventing
intracranial vascular thrombus formation, and for regulating cerebral vascular tone.70
Observational and experimental studies have shown that aSAH results in rapid EC
dysfunction with resultant disruptions in the blood-brain barrier, microvascular thrombus
formation and microvascular tone abnormalities.70,71 EC damage and dysfunction
appears to occur in vessels affected by aneurysm and subarachnoid hemorrhage, as well
as, vessels distant from these sites of injury.72,73 Experimental studies have shown that
this blood-brain barrier breakdown occurs within a few hours of injury through
combinations of both increased EC apoptosis and disruptions of EC tight junction
proteins.74-76 Likewise, abnormalities in nitric oxide (NO) production and degradation
as surrogates for EC microvascular tone abnormalities have been shown to occur after
aSAH.77 While not fully understood, these abnormalities appear to be linked to
increased perivascular inflammation and abnormal interactions between leukocytes and
EC after aSAH.70

1.5.2 Altered vascular smooth muscle responsiveness
Altered intracranial microvascular smooth muscle responsiveness after aSAH
results in impaired cerebral arterial autoregulation. Normally, the balance between
arteriolar vasoconstrictive and vasodilatory stimuli are tightly controlled and highly
responsive to changes in blood pressure to maintain a consistent cerebral blood flow
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across a variety of clinical conditions.78 Observational studies in aSAH patients,
however, have demonstrated that normal autoregulatory vasodilation does not occur as a
response to distal brain parenchyma hypoxia.79,80 Likewise, experimental studies have
similarly shown that altered intracranial vasoreactivity occurs in mouse models of aSAH
through direct and indirect measurements of microvascular lumen diameter.81,82 These
microvascular changes in humans and experimental models (increased vasoconstriction
and/or decreased vasodilation) appear to occur prior to or in the absence of the
development of large vessel vasospasm.40 Predictive models of DBI have been
developed, to varying degrees of success, using assessments of altered regional vascular
reactivity.83,84 The mechanism behind these observations remains undefined, although
acute inflammation and oxidative stress have both been hypothesized to play important
roles.85,86

1.5.3 Excitotoxic neuronal injury
Neuro-excitotoxicity injury occurs as a response to a host of toxic actions of
excitatory amino acids (EAA) on neurons.87 EAA, most importantly glutamate, are the
major excitatory neurotransmitters in the brain. Neurons that contain EAA play
important roles in learning and memory. While generally beneficial, overactivation of
these neurons or toxic release of EAA can be profoundly harmful and has been
implicated in neurodegenerative and neurovascular diseases.88 Neuronal excitotoxicity
from excess glutamate results in an excessive influx of ions across the neuronal cell
membrane, triggering harmful enzymatic cascades and cell death.89,90
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Glutamate levels have been compared between aSAH patients with and without
DBI. In these studies, glutamate is either measured directly in CSF or via microdialysis
of brain parenchyma.91,92 Studies have consistently demonstrated increased glutamate
levels in aSAH patients with DBI compared to those without aSAH or controls.93,94 It is
not clear whether this observation is a contributor to or a consequence of DBI in aSAH.
Further clinical and experimental research is needed to clarify the role that excitatory
amino acids, and glutamate in particular, play in the development of DBI in aSAH
patients.

1.5.4 Oxidative stress
Oxidative stress occurs when there is an imbalance in the production of free
radical reactive oxygen species (ROS) production and the removal of these ROS.95
Increased ROS may occur after aSAH due to neuronal mitochondrial oxidative stress,
hemoglobin free radical generation, disrupted antioxidant protection, and activation of
alternate enzymatic stress pathways.96 In experimental and clinical studies, oxidative
stress has been linked to DBI after aSAH.96,97 In experimental aSAH, markers of
oxidative stress, including elevated superoxide anion levels, are detected in the CSF of
animals with vasospasm at a greater concentration than in animals without vasospasm.98
In addition, treatment with various free radical scavengers decrease the occurrence of
vasospasm in experimental animals.96 The primary mechanism linking oxidative stress
to DBI is experimental alterations in the cerebrovascular contractile responses after ROS
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exposure.99,100 It is not clear whether these experimental studies translate to aSAH and
DBI in humans. Further clinical and experimental research to clarify the role of
oxidative stress in human aSAH and DBI is needed.

1.5.5 Apoptosis
Apoptosis, or programmed cell death, has been shown to occur after experimental
aSAH in mouse models.101,102 Apoptosis is initiated through either the so-called intrinsic
or extrinsic pathways that are each mediated by different biochemical mechanisms.103
The intrinsic pathway is activated through mitochondrial release of apoptotic stimulator
molecules; whereas, the extrinsic pathway is activated by specialized cell membrane
death receptors. In experimental aSAH, activation of both intrinsic and extrinsic
pathways has been described. Activation of these pathways in aSAH mouse models has
also been associated with DBI.104-106 It is not clear whether these animal studies
translate to aSAH and DBI in humans. Further clinical and experimental research to
clarify the role of apoptosis in human aSAH and DBI is needed.

1.5.6 Spreading depolarizations
Spreading depolarizations (SD) are spontaneous, repeating waves of neuronal cell
depolarizations that occur after ischemic, hemorrhagic or traumatic injuries to the
brain.107,108 SD worsen brain injuries by dramatically increasing oxygen consumption,
as well as, increasing the risk of seizure activity and cytotoxic edema formation.109,110 In
experimental animal models, SD have been observed shortly after aSAH and are
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correlated with worse outcomes.111,112 For these reasons, SD have also been associated
with DCI and some small observational studies support this link.112-114 Observational
data also indicates that SD can trigger intense vasoconstriction in ischemic brain,
although this appears to be reactive to ischemia, rather than causative.115 Its role in DCV
is not fully explored.116 Additional investigations of SD in aSAH patients are limited
because SD are not reliably detected using traditional transcranial electroencephalograms
(EEG) due to the low amplitude, short duration and specific anatomic locations of SD.117
In human and experimental observations, SD are studied using brain electrocorticograms
derived from electrodes applied directly to the external brain surface after or during
surgical craniotomy.117,118

1.6 Haptoglobin as a DBI Modifiable Factor
Haptoglobin (Hp) is a naturally occurring α-2 sialoglycoprotein produced in the
liver.119 Hp has a plasma half-life of approximately 5 days and is primarily responsible
for binding free-floating hemoglobin (Hb) in plasma, thereby preventing systemic iron
loss and reducing filtration-related kidney injury.120,121 Hp is an acute phase reactant and
its synthesis is stimulated by increased circulation of systemic proinflammatory
cytokines, including IL-1β, IL-6, and TNF-α.122 In response to these cytokines, increased
Hp synthesis occurs through complex interactions between different transcriptional
regulators and regions of the human haptoglobin gene.123,124 Hp also has a role in
modulating the inflammatory response to infection and injury through its effect on
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macrophage CD163.125 For these reasons, Hp may be a modifiable factor for the
development of DBI, based on the inflammation-mediated model, after aSAH.

1.6.1 Haptoglobin molecular structure
Hp exists primarily as a tetramer of 2 different polypeptide subunit chains, Hpα
and Hpβ. (Figure 3) These tetramers have a linear configuration, consisting of 2 internal
light Hpα chains linked together by a strong disulfide bond.126 On the outside of the
molecule, heavier Hpβ chains are linked to each of the inner Hpα protein chains. The
genes for both the Hpα and Hpβ chains are contiguously coded at chromosome location
16q22.127 Once the Hp proto-protein is synthesized, the individual chains are edited and
quickly polymerize to form the fully functional Hp molecule.119
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Figure 3: Illustration of a Typical Haptoglobin Molecule

Illustration of the 2 different haptoglobin (Hp) subunits and the disulfide bond in a typical
Hp molecule.
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1.6.2 Haptoglobin binding to free hemoglobin
As previously discussed, the primary role of Hp is to bind to free Hb to prevent
iron loss and kidney injury. To accomplish this, the heavy Hp β-chain units bind to the
β-globin Hb chain through a very strong non-covalent bond in a 1:1 interaction, forming
a large Hp-Hb protein complex.128 These protein complexes are ultimately internalized
and metabolized by circulating macrophages, via a process mediated through the
macrophage CD163 cell-surface receptor.129 Once internalized, lysosomal heme
oxygenase-1 (HO-1) is responsible for degradation of hemoglobin into free iron,
biliverdin and carbon monoxide.130

1.6.3 Haptoglobin scavenger receptor (CD163)
Macrophage CD163 (also sometimes known as M130, p155 or the Hb scavenger
receptor) is a 130 kDa glycoprotein almost exclusively expressed on cells derived from
monocytes, most commonly mature tissue macrophages, including hepatic Kupffer cells,
hepatic red pulp macrophages, thymic cortical macrophages and perivascular and
meningeal macrophages within the central nervous system.131 The CD163 receptor
belongs to a group of proteins known as scavenger receptor cysteine-rich (SRCR)
domain-containing proteins that generally function as pattern recognition receptors for
invading pathogens.131 CD163 consists of a short 24-residue trans-membranous section, a
cytoplasmic tail, and an extracellular portion that contains 9 different SRCR domains that
are essential for Hp-Hb complex endocytosis and play an important role in modulating
immune system activation.132 Cell membrane CD163 expression is increased by
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glucocorticoid administration and by the acute phase mediators, IL-6 and IL-10, whereas,
TNF-α, interferon and LPS result in decreased CD163 expression.133

Hp-Hb complexes interact with CD163 on the surface of monocytes and
macrophages through pH-dependent and calcium-mediated high-affinity binding.129,134
Studies have shown that CD163 can only bind Hp and Hb when they are complexed
together, suggesting that the combination, together, displays a unique epitope, allowing
for CD163 binding in this specific conformation.129,135 In addition, because Hp-Hb
binding to CD163 can be prevented by specific antibodies to or by proteolytic cleavage of
the SRCR domain 3, it is likely that this domain plays an important role in the complexreceptor binding mechanism.129,136

CD163 activation has important effects on both pro-inflammatory and antiinflammatory processes.125 Hp-Hb binding to CD163 increases macrophage release of the
anti-inflammatory agent, IL-10.137 IL-10, in turn, leads to increased CD163 expression,
increased Hb metabolism, and down-regulation of the inflammatory response to
extracellular Hb.125 Experimental cross-linked monoclonal antibodies to CD163 result in
increased macrophage release of IL-6 and GM-CSF.138

Activation of other CD163

binding sites, as may occur with tumor necrosis factor-like weak inducer of apoptosis
(TWEAK), bacterial cell membrane proteins, and viral envelope proteins, especially to
CD163 domains 2 and 3 lead to increased secretion of IL-1β, IL-6 and TNF-α and
decreased IL-10.125,139,140
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1.6.4 Haptoglobin phenotypes
Many different sizes and shapes of Hp molecules can be found in human
populations because three different Hp phenotypes exist in humans. These different Hp
phenotypes occur because of differences coded in the Hpα subunit. These different
versions of the Hpα gene allele are known as Hpα1F, Hpα1S, and Hpα2. The Hpα1F and
Hpα1S alleles both code for small proteins (~86 kDa) that are differentiated by only a
single amino acid, have only a single Hpβ binding site, and produce protein chains that
are clinically similar. For this reason, proteins created from either the Hpα1F or the
Hpα1S allele are referred to as Hpα-1. Mice and other non-human animals have only a
single phenotype and produce Hp molecules made only from Hpα-1 proteins.

The Hpα2 gene allele exists only in humans and is a gene sequence that appears to
be a fusion of both the Hpα1F and the Hpα1S alleles. The protein product from this
allele, called Hpα-2, is significantly larger than the Hpα-1 protein and contains two
Hpβ binding sites. Additional, very rare, mutations and fusions of the HPα allele have
also been reported. These rare mutations have not been associated with clinical disease.

Human Hp phenotypes are defined by differences in the linked light α-chain
protein products found in the final Hp molecule. When Hp molecules are formed from
only Hpα-1 proteins, the Hp phenotype is known as Hp1-1. When Hp molecules are
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formed from only Hpα-2 proteins, the Hp phenotype is known as Hp2-2. When Hp
molecules are formed from combinations of Hpα-1 and Hpα-2 proteins, the Hp
phenotype is known as Hp1-2.

Because the Hpα-2 protein is derived from 2 fused alleles, the protein has 2
distinct Hpβ binding sites, compared to the single binding site on the Hpα-1 protein.
This additional binding site allows Hp molecules with one or more Hpα-2 proteins to be
constructed with multiple different conformations and sizes, as seen in Figure 4. These
molecular size and chemic differences allowed the different Hp phenotypes to be first
discovered using gel electrophoresis of Hb-supplemented serum. 141 An ELISA test has
also been developed to detect these different Hp phenotypes.
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Figure 4: Illustration of Hp Phenotype Molecular Sizes and Shapes

Illustration of the different haptoglobin (Hp) subunits in the Hp molecules formed by
each of the Hp phenotype variants.
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1.6.5 Haptoglobin phenotype frequencies
The three primary Hp phenotypes (Hp1-1, Hp1-2 and Hp2-2) exist within
populations of patients at different frequencies, primarily dependent on the geographic
origins of the populations.119,142,143 The Hp2-2 phenotype occurs with the highest
prevalence among native Indian and Australian Aborigines, with reported 84% and 66%
penetration in these populations, respectively. 119 It is likely that the Hpα2 allele mutation
first occurred in one of these populations and then migrated due to selection pressure
throughout Asia, Europe, North American and South America. 144 Western European and
North American populations are characterized by a predominance of the Hp1-2
phenotype and sub-Saharan African populations are characterized by a predominance of
the Hp1-1 phenotype. Because of the “mixing pot” effect that exists in North America,
the reported Hp phenotype frequencies are different between Caucasians and AfricanAmericans with Caucasians demonstrating a ratio of 2.59 between the Hp2-2 and the
Hp1-1 phenotypes whereas African-Americans demonstrated a ratio of only 1.45,
primarily because of an increase in the frequency of the Hp1-1 phenotype.119 Different
ratios for Hp phenotype frequencies in specific population is likely to be additionally
dependent on the local populations, migration patterns, ethnic intermixing and disease
prevalence in the community.

1.6.6 Haptoglobin phenotypes and CD163 binding
Different Hp phenotypes bind CD163 with different binding affinities. CD163
has a 10-fold greater binding affinity for the Hp2-2 and Hp1-2 haptoglobin phenotypes
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than for the Hp1-1 phenotype.129 This has been hypothesized to occur because of either
an increased number of binding sites or a clustering of binding sites from the multimeric
variants of Hp2-2 and Hp1-2 compared to the linear Hp1-1 variant.129,135 This
phenomenon was termed “bonus effect of multivalency” and results in increased Hp-Hb
uptake, as well as, secondary effects within the macrophage, including increased
secretion of pro-inflammatory cytokines, including IL-1β, IL-6, IL-10 and TNF-α.135

1.6.7 Haptoglobin phenotypes and systemic diseases
Patients with different Hp phenotypes appear to have different outcomes in some
systemic diseases.145 Most notably, the Hp2-2 phenotype has been associated with an
elevated risk of coronary artery disease (CAD) and myocardial infarction, particularly in
diabetic patients.146-148 While still under investigation, CAD appears to occur more
frequently in Hp2-2 patients because of increased plasma iron accumulation, high-density
lipoprotein (HDL) oxidation, and atherosclerotic plaque development.149 The Hp2-2
phenotype has also been associated with a greater risk of hypertension, and hypertensive
Hp2-2 patients are more likely to need antihypertensive medications and to require
multiple drug combinations to achieve an appropriate blood pressure than are
hypertensive patients with the other Hp phenotypes.150,151 Likewise, the Hp2-2 phenotype
has been associated with an increased risk of peripheral vascular disease.152-154
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1.7 Haptoglobin Phenotypes in aSAH
Because blood containing both Hp and Hb is released into the subarachnoid space
after aSAH, the interaction between Hp, Hb, and CD163 may be an important cause of
DBI after aSAH. While the pathophysiologic basis for this hypothesis is not defined,
observational studies in humans and transgenic mice have attempted to clarify the
strength of this observation.

1.7.1 Human aSAH studies in patients with different Hp phenotypes
To date, several small human observational studies and a single meta-analysis
have evaluated clinical outcomes and DBI, including DCV and DCI after aSAH among
patients with different Hp phenotypes. 155-162 A summary of these published studies can
be found in Table 1 below. In general, most of these studies are small (<100 patients),
have variability in the prevalence of the Hp phenotypes in the target population, and
poorly evaluate DCV, DCI and/or clinical outcome, using in some cases, non-standard
definitions or assessments. Despite these significant limitations, the published studies
suggest an association exists between the Hp phenotype and DBI, especially DCV. An
association between DCI and clinical outcomes is much less clear from these studies.
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Table 1: Published Observational Studies of Hp Phenotypes in aSAH.
Author

Year

# aSAH % Hp2-2 DCV

DCI

Patients Patients

Clinical

Comment

Outcome

32

Borsody

2006

32

34

+

NA

+

Small study. DCV defined by both TCD and DSA.

Galea

2012

30

4

NA

NA

NA

Primarily focused on biochemical endpoints.

Ohnishi

2013

95

52

+

-

-

Demonstrated significant effect of Hp phenotype on DCV

Kantor

2014

193

31

NA

NA

+

Primarily evaluated long-term clinical outcome.

LeClerc

2015

74

32

+

-

-

Complex description of DCV using unvalidated

Murthy

2016

133

35

NA

NA

-

it
Evaluated infarction rather than DCV or DCI.

Kim

2018

87

45

+

+

NA

DCV defined only by DSA.

To clarify and evaluate the strength of the association between Hp and DBI in
aSAH patients, a meta-analysis of the 6 published studies was published in 2017.161 The
authors of the meta-analysis categorized the results of studies into short-term outcomes,
including DCV and DCI during hospitalization, and long-term outcomes, including
modified Rankin Scale (mRS) and Glasgow Outcome Score (GOS) between 1-3 months
after aSAH. Based on the 553 patients across these studies, the authors found an
association between Hp phenotype and both short-term and long-term outcomes. In their
data, the Hp2-2 phenotype was associated with more DCV and DCI when compared to
Hp1-1, Hp1-2, as well as, the combined Hp1-1 and Hp1-2 cohorts.

1.7.2 Experimental SAH studies in transgenic mice with different Hp phenotypes
Because mice and other non-human animals have only the Hp1-1 phenotype,
evaluations of DBI after experimental aSAH, including DCV and DCI in Hp2-2 animals
utilize transgenic models. To facilitate this type of research, a mouse Hp2 gene allele
was created by Levy and colleagues from a duplication of the wild-type Hp1 genetic code
for exons 3 and 4, similar to the type of event that likely created the Hp2 gene allele in
humans.163,164 In subsequent validation studies, the Hp molecules from transgenic Hp2-2
mice have been shown to have a similar size and shape to human Hp2-2 molecules and
the serum concentration of Hp has been shown to be similar between the wild-type Hp1-1
mice and the transgenic Hp2-2 mice.119,164
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To date, 5 studies, all from the same lab, have evaluated the effect of DBI in this
transgenic mouse model. In these studies, DCV was evaluated by measuring basilar
artery lumen patency after experimental SAH. This data was then reported as a percent
change in patency compared with control animals where a lower percentage was
equivalent to more DCV. DCI was evaluated using a simple, objective scale of
posturing, grooming and ambulation 24-hours after experimental SAH.165 This data was
reported as a score from 0-3 where a lower score was equivalent to more DCI.

Chaichana and colleagues published the first study specifically designed to
measures differences in lumen patency and activity level between Hp1-1 mice and Hp2-2
mice. In this study, Hp2-2 mice had significantly more lumen patency change (more
DCV) and worse activity level (more DCI).165 Subsequent studies primarily evaluated
potential DBI therapies, including a glutathione peroxidase mimetic, a NO donor in an
experimental polymer, L-citrulline and S-4-CPG.166-169 While these studies demonstrated,
to varying degrees, that lumen patency was worse in the transgenic Hp2-2 animals, there
was also a concerning variability in the reported lumen patency in the Hp1-1 groups
(82.3% to 71.5%) that was not present in the Hp2-2 groups. Despite this concern, the
experimental DBI therapies were all able to restore lumen patency. Activity level data
was inconsistent across the studies and the experimental DBI therapies, except systemic
L-Citrulline, were not able to restore activity levels after SAH.
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1.8 Soluble CD163 (sCD163)
Based on these human and animal studies, it seems plausible that different Hp
phenotypes may affect the inflammatory response after aSAH through activation of the
CD163. In addition, different Hp phenotypes may also affect the inflammatory response
through differential activation of a related molecule, soluble CD163 (sCD163). sCD163
is a free-floating form of macrophage CD163 found in plasma and other body
fluids.170,171 It is a large molecule (945 amino acids), containing portions of all nine of
the CD163 extracellular domains.172 While multiple avenues of research are ongoing,
the physiologic and pathologic roles of sCD163 are not fully known and its effect on
systemic and neurologic diseases remain poorly defined.

sCD163 is formed from enzymatic cleavage of the extracellular portions of the
CD163 protein from the trans-membranous portions by the ADAM17/TACE enzyme.173
ADAM17/TACE resides in the macrophage membrane and becomes activated by various
physiologic and pathologic stimuli.174 When activated, ADAM17/TACE results in the
cleavage and release of more than 40 membrane-bound proprotein substrates, including
sCD163.174,175 Increased sCD163 release by ADAM17/TACE is stimulated by Toll-like
receptor (TLR) activation and other inflammatory mediators, oxidative stress, and
thrombin.176-179 For this reason, sCD163 has been hypothesized to have a modulator role
in acute and chronic systemic inflammation.175
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1.8.1 sCD163 in systemic diseases
sCD163 has been investigated in various diseases associated with deranged
inflammation, including sepsis, hemophagocytic syndrome, liver failure, and
disseminated intravascular coagulation (DIC). In experimental sepsis models, plasma
sCD163 concentration rapidly rises after infectious or inflammatory insult occurs.180
Clinical studies of bacteremia and septic shock in humans have demonstrated that a
significantly elevated sCD163 concentration is associated with a worse prognosis than
only a moderate increase in concentration.181,182 Likewise, in hemophagocytic
syndrome, a disease associated with macrophage hyperactivity and inappropriate
macrophage endocytosis of normal blood cells, very high sCD163 concentrations occur
early in disease and resolve as a marker of response to disease treatment.183,184 sCD163
is also significantly increased in patients with active liver disease such as cirrhosis and
hepatitis.185 In these conditions, a significant increase in sCD163 concentration is also
correlated with a worse prognosis.186,187 Finally, in DIC, sCD163 concentration are also
significantly increased and can be correlated with abnormalities in D-dimer
concentrations.179

1.8.2 sCD163 in neuroinflammatory diseases
Studies of plasma and CSF sCD163 concentrations in neuroinflammatory diseases
are less well described. To date, sCD163 has been investigated in multiple sclerosis,
infectious encephalopathy, and chronic inflammatory demyelinating polyneuropathy.
The majority of these investigations are small, single-center evaluations of multiple
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biomarkers of disease or disease progression in a known population.188-190 In each of
these diseases, increased concentrations of plasma and/or CSF are indicative of disease
and/or its progression.

1.8.3 sCD163 in aSAH and other types of hemorrhagic stroke
sCD163 has been investigated in both intracerebral hemorrhage (ICH) and
subarachnoid hemorrhage. ICH is similar to aSAH but results in bleeding within the
brain tissue itself and is associated with hypertension, head injury, and the use of
anticoagulation therapies, such as warfarin, clopidogrel, and direct oral anticoagulants
(DOAC).191-193

A recent observational study grouped 54 ICH patients according to their plasma
sCD163 concentration determined within 24 hours of injury.194 Despite having similar
hematoma size at admission, patients with a lower initial sCD163 concentration had a
higher hematoma volume at PBD14 and a slower calculated hematoma absorption rate
than did patients with a higher initial sCD163 concentration. These patients also had
worse recovery at PBD14, PBD30, and PBD90 day. The authors concluded that
sCD163 may have an important role in the absorption of blood after ICH, thereby
affecting overall recovery and prognosis.

In a second study of 51 ICH patients, serum and CSF sCD163 concentrations
were obtained at prespecified time points up to PBD10.195 In this population, the serum
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sCD163 concentration remained relatively stable from PBD1 through PBD8 before
significantly increasing on PBD10; however, the CSF sCD163 concentration had
significant variability at all time points and no specific pattern was identified. Patients
with lower serum sCD163 concentrations at PBD2 had greater hematoma volume and
were more likely to have perihematomal edema. There were no differences in CSF
sCD163 concentrations between patients with different perihematomal volume or edema.
The authors also concluded that sCD163 may have an important role in the absorption of
intracerebral blood and further hypothesized that altered neuroinflammation as a
consequence of sCD163 may play a role in the observed differences in perihematomal
edema.

Only a single study has evaluated sCD163 concentrations in aSAH.156 In this
study, serum and CSF concentrations of sCD163 were analyzed from 30 aSAH patients
and 20 control patients. Unfortunately, neither the serum or CSF sampling time points
were described. In their analysis, there was no difference in serum sCD163
concentrations between the control group and patients with aSAH, whereas, the CSF
sCD163 concentration was greater in aSAH patients than in control patients. The
authors hypothesized that the normal Hp-scavenging mechanism was rapidly
overwhelmed during aSAH, causing rapid release of sCD163, from macrophage cells.
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1.9 Role of Haptoglobin and sCD163 in Inflammation-Mediated DBI Model
Based on these observational and experimental studies, Hp appears to play an
important role in the inflammation-mediated model of DBI. I propose that, in this
model, Hp is a modifier factor that can either drive the development of DBI through an
effect on the linking trigger between subarachnoid hemorrhage and the activated
inflammatory response or through a direct effect on inflammatory response itself. (Figure
5) In this updated model, Hp phenotype is the key driver for this interaction and
incorporates the observed differences in DBI outcomes for the different Hp phenotypes.
Based on this updated model, the different Hp phenotypes should also demonstrate
different inflammatory responses, as well as, different rates of DCV and DCI after aSAH.
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Figure 5: Updated Inflammation-Mediated Model of DBI

An updated version of the complex inflammation-mediated model of Delayed Brain
Injury (DBI) that incorporates soluble CD163 (sCD163) and haptoglobin (Hp) phenotype
as important modifiers of the activated inflammatory response.
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Likewise, sCD163 may play an important role in this DBI model. I propose that,
in this model, sCD163 is the linking trigger between subarachnoid hemorrhage and the
activated inflammatory response. (Figure 1.5) Based on this updated model, changes in
sCD163 should be associated with differences in the activated inflammatory response, as
well as, different rates of DCV and DCI after aSAH. Importantly, sCD163 activity may
also be modifiable by Hp through differential binding and secondary activation by the
different Hp phenotypes, further integrating both sCD163 and Hp into this complex,
inflammation-mediated model of DBI.

1.10 Conclusions
This chapter introduced the key features of aSAH, described the importance of
delayed brain injuries (DBI) and their potential pathophysiologic mechanisms, and
detailed the potential effect that different haptoglobin (Hp) phenotypes have on DBI and
clinical outcomes. In addition, this chapter concluded with a discussion of the potential
mechanisms that might link the Hp phenotypes and sCD163 to the development of DBI
and long-term clinical outcomes through an inflammation-mediated model. The
following chapters detail my approach to evaluating these mechanisms through the
development of a prospectively-collected aSAH biobank and the use of this biobank to
evaluate the effect of different Hp phenotypes on systemic and CSF inflammatory
cytokines and sCD163 at multiple time points.
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CHAPTER 2: DEVELOPMENT AND RESULTS OF ANEURYSMAL
SUBARACHNOID HEMORRHAGE BIOBANK

2.1 Introduction
This chapter describes the successful development of a single-center, prospective
aSAH biobank at the University of Kentucky. This biobank is needed to facilitate future
research because the rate of annual rate of hospitalization for aSAH is relatively low, the
potential data points, including demographic, disease-specific, and clinical outcome data,
are not routinely collected in the EMR or other medical records, and biofluid sampling is
not routinely performed at pre-specified time points. This chapter will discuss the
development of protocols for screening and recruitment of subjects, definitions of clinical
variables and outcomes, and protocols for biofluid sampling, preparation, and storage.
This chapter also reports the results of these screening and recruitment protocols and
important demographic and clinical outcome data generated from subjects recruited to the
biobank over a 2-year period.

2.2 Methods
2.2.1 Study design
To facilitate current and future research in aSAH, a prospectively collected
biobank of aSAH patients admitted to the University of Kentucky Chandler Medical
Center was designed. This biobank includes demographic data, disease-specific data,
clinical outcome data, as well as, plasma and CSF biofluids. All study procedures for
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this biobank were approved by the University of Kentucky Institutional Review Board
(IRB) prior to subject enrollment and data collection. Access to the biobank data and
biofluid samples is limited to study-related personnel but deidentified data may be
available for future IRB-approved research with principal investigator (PI) approval.

2.2.2 Study population
All adult patients (age ≥ 18 years) admitted to the University of Kentucky
Chandler Medical Center between July 1, 2018 and June 30, 2020 with angiographicallyproven aneurysmal subarachnoid hemorrhage who were likely to survive to, at least,
PBD14 and had an EVD placed were considered for biobank inclusion.

Patients were excluded from this biobank project if consent was not obtained by
PBD3, if they received blood or blood product transfusion prior to PBD3 sampling, if
they died prior to PBD3 or were unlikely to survive to PBD14, as determined by their
neurosurgical or neurocritical care teams, had angiographic evidence of vasospasm on or
before PBD3, had pre-existing neurologic injury that impaired recovery or survival, or
had pre-existing systemic or neurologic inflammatory disease.

2.2.3 Initial screening procedure
To enroll subjects in this biobank, all SAH patients were evaluated for the defined
screening criteria prior to being approached for consent by biobank personnel. These
screening criteria were implemented to reduce the potential emotional or psychological
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burden of research participation for patients and/or their families who would not,
ultimately, be enrolled in the biobank. Patients and/or their LAR were not approached
for consent if they had a non-survivable neurologic injury, if no EVD was placed by
PBD3, or if no aneurysm was identified on radiographic or angiographic testing by
PBD3. This information was obtained from the neurosurgery or neurocritical care teams
at the time of biobank team notification.

2.2.4 Consent of impaired subjects procedure
All aSAH patients who met screening criteria were then approached for informed
consent. Because aSAH patients may have impaired consciousness and/or thinking
processes that can interfere with their decision-making capacity, special procedures were
used to obtain informed consent. (Figure 6) For patients with a GCS ≤ 8 or for patients
with a GCS > 8 who were receiving continuous infusions of sedative medications that
could not be temporarily discontinued, the LAR was approached for informed consent.
For patients with a GCS > 8 who were receiving continuous infusions of sedative
medications that could be temporarily discontinued, sedation was discontinued, and the
patient was monitored until they were awake. At that point, the University of California,
San Diego Brief Assessment of Capacity to Consent (UBACC) tool was used to evaluate
the capacity to provide consent.196 For patients with a GCS > 8 not receiving continuous
infusions of sedation medications, the UBACC tool was used to evaluate the capacity to
provide consent.
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Figure 6: Process to Obtain Informed Consent for Biobank Subjects

A flow diagram of the process used to obtain informed consent for the biobank. The
process is designed to assess the decision-making capability of the patient using a
combination of Glasgow Coma Scale (GCS) and the University of California San Diego
Brief Assessment of Capacity to Consent (UBACC), a validated research tool.
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The UBACC tool is a 10-item scale, utilizing a set of standardized questions, with
a focus on evaluating whether the patient has an understanding and an appreciation of the
information concerning the research protocol.196 The response to each question is scored
on a scale from 0-2, based on the appropriateness of the patient’s response to a set of
standardized questions. The scores from each question are then totaled. A total score ≤
14 is consistent with impaired decision-making capacity. In this project, the LAR was
approached for informed consent if the patient’s UBACC score was less than or equal to
14; whereas, the patient was approached for informed consent if their UBACC score was
greater than 14, the patient was approached for informed consent. All decision-making
capacity assessments using the UBACC tool were performed by a single researcher. The
instrument used for UBACC assessments can be found in Appendix 1.

If the LAR was approached for initial consent due to impaired decision-making
capacity, the patient was re-assessed for improvement in decision-making capacity prior
to each biospecimen collection point using the process described above and illustrated in
Figure 6. If, at any point, the patient achieved a UBACC score > 14, the patient was
approached for informed consent for the research protocol prior to biospecimen
collection. Patient refusal of informed consent terminated the patient’s participation in
the research protocol.
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2.2.5 Clinical care of research subjects
Subjects enrolled in the aSAH Biobank received routine standard of care
diagnostic and therapeutic modalities. There were no changes to their care, other than
blood and CSF sampling, related to their participation in this biobank. For all subjects,
blood pressure was controlled with nicardipine to target systolic blood pressure (SBP) ≤
140 mmHg prior to aneurysm obliteration. After obliteration, mean arterial pressure
(MAP) was maintained within a range of 60-100 mmHg with SBP goal relaxed to ≤ 200
mmHg, unless otherwise indicated. Aneurysm obliteration therapy was performed
within 24 hours of hospitalization. All subjects received nimodipine therapy for 21 days
underwent daily TCD scanning for at least the first 14 days after aneurysm rupture,
unless they were discharged from the hospital prior to this time point.

Patients with symptomatic or suspected DCV underwent DSA and intra-arterial
injection of verapamil at the discretion of the attending or interventional neurosurgeon.
Patients with DCI were treated with therapeutic hypertension (MAP goal >100 mmHg)
and, if symptoms did not resolve, DSA with intra-arterial injection of verapamil within
vasospastic vessels. Patients with resistant DCV or DCI underwent periodic DSA and
high-dose milrinone infusion until neurologic status improved or PBD14, whichever
occurred earlier. Deviations from these practices were dictated by the attending
neurosurgical or neurocritical care teams based on the individual patient outcomes and
clinical course.
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2.2.6 Demographic and disease-specific data collection
Following informed consent, baseline and demographic data was collected from
the patient, the patient’s family, and the electronic medical record (EMR). All data was
recorded directly into an IRB-approved online database. Instruments used for this data
collection can be found in Appendix 2.

Disease severity for aSAH patients was collected using both the Hunt & Hess
scale (HH) or the World Federation of Neurologic Scale (WFNS).197-200 These disease
severity grading systems are most commonly associated with hospital and/or 30-day
mortality.15 The HH score was determined at the time of hospital admission from
observed clinical features. (Table 2) When possible, patients were scored prior to
administration of sedation or before procedures such as endotracheal intubation are
performed. If patients were already intubated or were receiving sedation, sedation was
held until a neurologic examination could be performed.

Table 2: Hunt & Hess Score
Score

Description

1

Mild headache

2

Moderate-severe headache, nuchal rigidity, or cranial nerve deficit

3

Drowsiness, confusion, focal neurologic deficit

4

Stupor or severe hemiparesis

5

Coma or decerebrate posturing
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The World Federation of Neurological Surgeons (WFNS) scale score was also
collected at the time of hospital admission.200 The WNFS scale was developed to
incorporate more objective features, such as the Glasgow Coma Scale (GCS) score and
the absence or presence of motor deficits, into severity grading. (Table 3) Like the
procedure for HH scoring, WFNS scoring was performed prior to sedation and/or
intubation, when possible, and after sedation was temporarily held if the patient was
intubated and sedated prior to hospitalization.

Table 3: World Federation of Neurological Surgeons (WFNS) Score
Score

Glasgow Coma Scale (GCS) Score

Motor Deficit

1

15

Absent

2

13 – 14

Absent

3

13 – 14

Present

4

7 – 12

Absent or Present

5

3–6

Absent or Present

6

Death

NA

Based on associated mortality rates, for both HH and WFNS, scores from 0-3
were considered “favorable” or and scores 4-6 were considered “poor”.15
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The Modified Fischer Scale score was also collected for each patient from initial
computed tomography (CT) scan of the head. (Table 4) The mFS score is correlated with
risk of DCV. While, mFS scores 0-3 are associated with only a slight increase in the risk
of DCV, mFS score =4 is associated with significantly higher risk (OR=2.2, 95% CI 1.43.5).25 For this reason, mFS scores of 0-3 were considered “favorable” and mFS scores
of 4 were considered “poor”.
Table 4: Modified Fischer Scale Score
Score

SAH (Focal or Diffuse)

IVH

0

No SAH

Absent

1

Thin SAH layer

Absent

2

Thin SAH layer

Present

3

Thick SAH layer

Absent

4

Thick SAH layer

Present

2.2.7 Determination of delayed brain injury diagnoses
The presence or absence of DCV was determined from TCD data from PBD3
through PBD14. The left and right middle cerebral artery (MCA) and internal carotid
artery (ICA) blood flow velocities were recorded daily from the EMR. Subjects were
considered to have DCV if they had either: (1) an MCA mean flow velocity more than
120 cm/sec and an MCA/ICA velocity ratio greater than 3.0 or (2) angiographic evidence
of intracranial arterial vasospasm documented in the EMR. The presence or absence of
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DCV was recorded on the PBD30 case report form. Missing values, as may occur from
patient or technical factors reducing the ability to visualize either the MCA or ICA
arteries with TCD, were treated as negative DCV results.

The presence or absence of DCI was determined from Glasgow Coma Scale
(GCS) data available in the EMR on PBD3 through PBD14. Patients with a decrease in
their GCS of more than 2 points during a 24-hour period that could not be attributed to
other medical sources such as sedation, infection or seizures were considered to have
DCI. The presence or absence of DCI was recorded on the PBD30 case report form.
Missing data were treated as negative DCI results.

The presence or absence of delayed cerebral infarction was determined from CT
and/or MRI scans available in the EMR on PBD3 through PBD90. Patients with
evidence of new cerebral infarction, as reported by a neuroradiologist, that were not
present on scans performed prior to PBD3 were considered to have delayed cerebral
infarction. The presence or absence of delayed cerebral infarction was recorded at the
PBD90 follow-up form. Missing data were treated as negative delayed cerebral
infarction results.

2.2.8 Clinical outcome and disability scoring
All patients were evaluated for survival at the time of hospital discharge. In
addition, all patients were evaluated for survival, as well as, continued neurologic
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disability on about PBD30 and PBD90 using the modified Rankin scale (mRS) and the
Glasgow Outcome Scale Extended (GOSE). The scale scores for all research subjects
were obtained by the PI using standard scripts. Scale scores for research subjects still
admitted to the hospital at the time of examination were obtained at the bedside from the
subject and/or the LAR. Scale scores for research subjects not admitted to the hospital
was obtained via telephone conversation with the subject and/or the LAR. Telephone
contact was attempted daily for 3 days and then at 1 week and 2 weeks after both PBD30
and PBD90, until contact with the patient or LAR was made. If no contact was made
after these attempts, the patient was considered lost to follow-up. No contact was
attempted for subjects who had previously died. These subjects were given scale scores
of mRS=6 and GOSE=1 at PBD30 and/or PBD90. mRS scores 0-3 were considered
“favorable” and mRS scores 4-6 were considered “poor”; whereas, GOSE scores 5-8
were considered “favorable” and GOSE scores 1-4 were considered “poor”.

2.2.9 Biofluid sample preparation and storage
All biofluids (blood and cerebrospinal fluid) were collected at pre-defined
specific time points by a trained member of the research team. Biofluids were collected
on PBD3, PBD5, PBD7, and PBD10 using IRB-approved protocols. All biofluid
processing procedures were completed within 30 minutes of sampling. Sampling and
process procedures that were completed in more than 30 minutes were marked as
protocol violations.
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Blood samples were collected directly from research subjects via an indwelling
arterial catheter into 10 mL plasma tubes with 18 mg K2 EDTA (Becton, Dickinson and
Company, Franklin Lakes, NJ). Blood samples were collected according to local
hospital protocols to reduce the risk of infectious or mechanical complications. The 10
mL blood sample was then transported on ice to the research laboratory and spun in a
refrigerated centrifuge (Allegra 6KR Centrifuge, Beckman Coulter Life Sciences,
Indianapolis, IN) at 1200 x g for 10 minutes to separate the plasma from the red blood
cells, leukocytes and platelets. The plasma portion was then pipetted into 6 separate 250
mcl aliquots and stored in a -80 C freezer until needed for analysis. Blood sample waste
was destroyed per an approved biosafety protocol.

CSF samples were collected directly from research subjects via an indwelling
extraventricular drain (EVD) into 15 ml polypropylene conical tubes. CSF samples (3
mL) were collected according to local hospital protocols to reduce the risk of infectious
or mechanical EVD complications. CSF samples were transported on ice to the
laboratory and spun in a refrigerated centrifuge (Allegra 6KR Centrifuge, Beckman
Coulter Life Sciences, Indianapolis, IN) at 1200 x g for 10 minutes to separate CSF from
red blood cells, leukocytes, platelets and other debris. CSF was then pipetted into 6
separate 250 mcl aliquots and stored in a -80 freezer until needed for analysis. CSF
sample waste was destroyed per an approved biosafety protocol.
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2.2.10 Haptoglobin phenotype analysis
After all subjects had been recruited, the haptoglobin phenotype (Hp1-1, Hp1-2 or
Hp2-2) was determined for each research subject using a commercial ELISA kit from
Savyon Diagnostics (Technion, Israel). (Catalog #A-710-01M, Lot # 710-A0151500,
Exp. 1/2021) by the University of Kentucky Center for Clinical and Translational Science
(CCTS) Biomarker Analysis Laboratory (BAL). This Hp phenotype ELISA test utilizes a
monoclonal antibody (mAb) against the Hp molecule, utilizing the varying number of
binding sites, to differentiate between the Hp phenotypes.201 The specific steps used by
the UK CCTS BAL in this analysis are described in Appendix 3. Subjects were defined
as either Hp1-1, Hp1-2 or Hp2-2, based on the results of the ELISA. Because a recent
meta-analysis demonstrated that Hp1-1 and Hp1-2 patients had similar rates of DBI
compared to Hp2-2 patients, subjects were further defined as either Hp1 class (subjects
with Hp1-1 or Hp1-2 phenotypes) or Hp2 class (subjects with Hp2-2 phenotype).161

2.2.11 Data management plan
A data management plan was created and approved by the IRB prior to studyrelated procedures. All research data was entered directly into an online, browser-based
research database (REDCap) by IRB-approved study personnel. REDCap utilizes user
authentication and role-based security, electronic case report forms (CRFs), real-time
data validation, data integrity checks, centralized data backup, and data export options to
common statistical packages to facilitate data collection, storage and dissemination across
many different clinical and research projects.202,203 The REDCap database was
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developed at Vanderbilt University, was first launched in 2004, and has gained
widespread support since that time, in large part through its use in an evolving
consortium of academic institutions, including more than 3200 organizations in more
than 120 countries.204

All subject data was collected at the time of consent, as well as at 7 specific study
visits (PBD3, PBD5, PBD7, PBD10, PBD14, PBD30 and PBD90). Online CRFs were
completed at each visit Appendix 2. Results of Hp phenotype analysis for each subject
were also entered into the REDCap database. Data retrieval from the EMR and entry
into the database was verified on a weekly basis by the PI. All data errors were
immediately corrected in the online database by the PI.

2.2.12 Safety management plan
A subject safety management plan was created and approved by the IRB prior to
study-related procedures. The major risks to subjects in this study were related to CSF
sampling, blood sampling and breaches of confidentiality. To minimize risks from CSF
and blood sampling, these procedures were performed under sterile conditions, according
to pre-specified protocols, as previously described in this chapter. To minimize risks
from breaches of confidentiality, subjects were identified only with the use of a study
identification number for study-related data collection.
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All research subjects were monitored for the maintenance of safety by the PI.
Subjects with known or suspected adverse events (AE) or series adverse events (SAE)
were evaluated, documented and reported to the IRB per standard research policies. The
PI and clinical co-investigators reviewed the AE/SAE reports after the first 10 patients
completed the research protocol to evaluate patient safety, data accuracy and protocol
compliance. Because there were no AE/SAE to report at that time, interim data safety
analysis was performed after every additional 20 patients completed the research
procedures. Reports of the interim data safety analyses were submitted to the IRB on an
annual basis.

2.2.13 Statistical analysis plan
A statistical analysis plan was created in consultation with a statistician from the
University of Kentucky Applied Statistics Lab. All categorical and ordinal data were
reported as count and percentage. Continuous data were first analyzed for normal
distribution. Non-normal, continuous data distributions were described by median and
interquartile range (IQR). Normal, continuous data distributions were described by
mean and standard deviation (SD). For tables and analyses with mixed normal and nonnormal data distributions, data were described by median and IQR.

For hypothesis testing involving categorical or ordinal data, the Fischer’s Exact or
Pearson Chi-Squared tests were used, as appropriate. For hypothesis testing involving
non-normal, continuous data, the independent samples median test was used. For
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hypothesis testing involving normal, continuous data, the unpaired, two-tailed, t-test was
used. For all hypothesis testing, a p-value <0.05 was considered significant. All
statistical analyses were completed with IBM SPSS version 25 (IBM Corp, Armonk,
NY).

2.3 Results
2.3.1 Study recruitment
From July 1, 2018 – June 30, 2020, 106 patients were admitted to the University
of Kentucky Chandler Medical Center with subarachnoid hemorrhage. Of these, 44
patients (41.5%) met the initial screening criteria and were approached for study consent.
Informed consent was obtained from 32 patients (30.2%). Of these, 25 patients (23.6%)
were recruited to participate in the biobank during the target study period. The causes
for screening failures, consenting failures, and subject exclusions during the study period
are described in Figure 7. “No EVD placed” was the most frequent cause of failed
screening, resulting in 79.0% of all failed screening occurrences. “No family available”
was the most frequent cause of failure to obtain consent, resulting in 75% of all
consenting failures. “Admitted after PBD3” was the most frequent cause of subject
exclusion, resulting in 42.9% of all exclusions.
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Figure 7: Flow Diagram of Screening and Recruitment to Biobank

Flow diagram describes the subject screening and recruitment success of biobank project.
Only 25 patients admitted with aneurysmal subarachnoid hemorrhage were ultimately
enrolled in the project. The major causes of screening failure were “No extraventricular
drain (EVD) placed”, “Patient died or not survivable”, and “No family available”.
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During the study period, the overall frequency of SAH admissions remained
relatively stable over the 2 years with 53 patients admitted in year 1 and 53 admitted in
year 2. Of these, 20 patients (80%) were enrolled in this biobank in year 1 and 5 patients
(20%) were enrolled in this biobank in year 2. (Figure 8) Over the 2-year period, there
were approximately 3.4 patients admitted per month; however, the subject enrollment
rate significantly decreased from 1.7 cases per month in year 1 to 0.42 patients per month
in year 2. Table 2.1 describes the differences in the rates of screening failures exclusions
between the year 1 and year 2. There were no statistically significant differences in the
causes of recruitment failure between the 2 years.
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Figure 8: Biobank Screening and Recruitment During Study Period

Line graphs of the number of cumulative subjects screened and recruited per month over
the 2-year study period. The number of cumulative subjects screened was nearly linear
over this time period; whereas, the number of subjects recruited did not significantly
increase after March 2019. This resulted in fewer enrolled research subjects than
expected at the end of the study period.
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Table 5: Causes of Biobank Recruitment Failure
Year 1

Year 2

(N=34)

(N=47)

22

27

(64.7%)

(57.4%)

3

7

(8.8%)

(14.9%)

1

2

(2.9%)

(4.3%)

3

6

(8.8%)

(12.8%)

3

0

(3.3%)

(0.0%)

0

3

(0.0%)

(6.4%)

1

1

(2.9%)

(2.1%)

1

0

Neurologic Disease

(2.9%)

(0.0%)

Vasospasm before

0

1

(0.0%)

(2.1%)

No EVD Placed

Not Survivable

No Aneurysm

LAR Not Available

Refused Consent

Admitted after
PBD3
Pre-existing
Inflammatory

p-value

0.51

0.41

0.76

0.58

NA

NA

0.82

Disease
Pre-existing

PBD3
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NA

NA

Of note, due to COVID-19, a severe respiratory system disease caused by
infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
patient visitation policy at the University of Kentucky Chandler Medical Center was
restricted on March 19, 2020. At that time, visitation was limited to 1 family member
per patient. On March 24, 2020, a “no visitation” policy was implemented across the
hospital until May 18, 2020, a period of 55 days (approximately 7.5% of the total study
period). During this period, 13 patients were admitted to the University of Kentucky
Chandler Medical Center with SAH. Of these patients, 7 did not meet screening criteria
and 5 met screening criteria but were not enrolled in the study because the LAR could not
be approached for consent. These 5 patients accounted for a significant percent (62.5%)
of all patients who were not enrolled because the LAR could not be approached for
consent. During this period, 1 patient met screening criteria and was enrolled in the
study. This patient was able to provide their own written documentation of informed
consent.

2.3.2 Demographic and delayed brain injury analysis
Baseline demographic and disease-specific data for all subjects in the biobank is
summarized in Table 6.
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Table 6: Overall Biobank Subject Demographic and Disease-Specific Data
Results
N=25
Age (years)

63 (49-66)

Gender (male)

10 (40%)

Height (cm)

167.6 (162.5 – 177.8)

Weight (kg)

93.5 (70.0 – 113.6)

Body Mass Index (kg/m2)

33.2 (26.6 – 37.1)

Favorable HH Score (1-3)

22 (88%)

Favorable WFNS Score (1-3)

17 (68%)

Favorable MFS (3)

9 (36%)

Aneurysm Location (Anterior)

16 (64%)

Obliteration Therapy (Coiled)

24 (96%)

Eleven patients (44%) in the biobank developed DCV after aSAH. Baseline
demographic and disease-specific data for subjects in the biobank by their DCV status are
summarized in Table 7. There were no statistically significant differences in these data
between subjects with and subjects without DCV in this biobank.
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Table 7: Biobank Subject Demographic and Disease-Specific Data by DCV Status
No DCV

DCV

(N=14)

(N=11)

Age (years)

65 (53-73)

53 (46-63)

0.09

Gender (male)

7 (50.0%)

3 (27.3%)

0.41

168.9

167.6

0.93

(162.5 – 177.8)

(162.5 – 170.1)
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106.9

(69.2 – 111.3)

(86.1 – 113.4)

30.4

37.1

(26.5 – 33.9)

(30.8 – 40.4)

14 (92.9%)

9 (81.8%)

0.56

10 (71.4%)

7 (63.6%)

1.00

Favorable MFS (3)

9 (64.3%)

5 (45.5%)

0.44

Aneurysm Location

8 (57.1%)

8 (72.7%)

0.68

14 (100.0%)

10 (90.9%)

0.44

Height (cm)

Weight (kg)

Body Mass Index (kg/m2)

Favorable HH Score

p-value

0.21

0.08

(1-3)
Favorable WFNS Score
(1-3)

(Anterior)
Obliteration Therapy
(Coiled)
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Seven patients (28%) in the biobank developed DCI after aSAH. Baseline
demographic and disease-specific data for subjects in the biobank by their DCI status are
summarized in Table 8. There were no statistically significant differences in these data
between subjects with and subjects without DCI in this biobank.
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Table 8: Biobank Subject Demographic and Disease-Specific Data by DCI Status

Age (years)
Gender (male)
Height (cm)

Weight (kg)

Body Mass Index
(kg/m2)
Good Hunt Hess Score

No DCI

DCI

p-value

(N=18)

(N=7)

63 (49.8 – 68.5)

54 (50.5 – 67)

0.95

6 (31.6%)

4 (57.1%)

0.38

166.4

167.6

0.90

(162.5 – 177.8)

(165.1 – 170.1)

89.8

107.2

(68.9 – 111.9)

(81.6 – 112.9)

31.6

37.1

(26.5 – 34.2)

(29.9 – 38.4)

6 (31.6%)

6 (85.7%)

0.03

5 (26.3%)

5 (71.4%)

0.08

4 (21.1%)

5 (71.4%)

0.06

4 (21.1%)

5 (71.4%)

0.06

7 (36.8%)

6 (85.7%)

0.07

0.40

0.23

(1-3)
Good WFNS Score (13)
Good Modified Fischer
Score (4)
Aneurysm Location
(Anterior)
Obliteration Therapy
(Coiled)
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Only 2 patients (8%) developed delayed cerebral infarction after aSAH. Both
patients were relatively young, aged 46 and 54. One patient was male, and one patient
was female. Their Hunt and Hess Scores were 4 and 3, their WFNS scores were 5 and 2,
and their modified Fischer scores were 4 and 4, respectively. Both patients had anterior
aneurysms that were obliterated with endovascular (coiling) therapy. Both patients had
DCV and one of the patients also had DCI.

2.3.3 Clinical outcome and disability scoring analysis
Of the 25 subjects recruited to the study, 23 subjects (92%) survived to discharge
and 2 subjects (8%) died prior to hospital discharge. One patient died after PBD14 due
to withdrawal of life-supporting care after spontaneous rupture of a second aneurysm.
The other patient died after PBD10 due to withdrawal of life-supporting care after
repeated episodes of DCV and continued poor neurologic status.

Of the 23 subjects who survived to hospital discharge, disability scores were
obtained from 22 subjects (88%) at PBD30. Three subjects (12%) that were discharged
alive could not be contacted at PBD30 follow-up. At PBD90 follow-up, disability scores
were obtained from 23 subjects (92%). All subjects who could not be contacted at
PBD30 follow-up were contacted at PBD90 and 2 (8%) subjects that were contacted at
PBD30 follow-up could not be contacted at PBD90 follow-up. Unfortunately, one
subject died at an outside hospital between PBD30 and PBD90 due to pulmonary
embolism.
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The results of mRS and GOSE scale scoring at PBD30 and PBD90 are shown in
Figure 9 and Figure 10, respectively. There were significantly more subjects with good
mRS scores (0-3) at PBD90 than at PBD30 (20 (87.0%) vs. 13 (59.1%), p=0.034).
Likewise, there were significantly more subjects with good GOSE scores (5-8) at PBD90
than at PBD30 (18 (78.3%) vs. 8 (36.4%), p=0.004).
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Figure 9: Biobank Subjects mRS Scores at PBD30 and PBD90

Graphs of the number of subjects with each modified Rankin Scale (mRS) score at postbleed day 30 (PBD30) and post-bleed day 90 (PBD90). There were more subjects with
scores 0-2 at PBD90 than at BPD30, suggesting that more subjects had better recovery, as
determined by mRS, at the later time period than at the earlier time point.
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Figure 10: Biobank Subjects GOSE Scores at PBD30 and PBD90

Graphs of the number of subjects with each Glasgow Outcome Scale Extended (GOSE)
score at post-bleed day 30 (PBD30) and post-bleed day 90 (PBD90). There were more
subjects with scores 5-8 at PBD90 than at BPD30, suggesting that more subjects had
better recovery, as determined by GOSE, at the later time period than at the earlier time
point.
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Comparisons of the number and percentages of biobank subjects with and without DCV
and DCI with good mRS and GOSE scores at PBD30 and PBD90 are described in Table
9 and Table 10, respectively. When comparing subjects with and without DCV, there
was a greater percentage of subjects without DCV and good mRS scores at both PBD30
and PBD90, although these differences were not significant. Likewise, while there was
a greater percentage of subjects without DCV and good GOSE scores at both PBD30 and
PBD90, these differences were also not significant. When comparing subjects with and
without DCI, there were significantly more subjects without DCI who had good mRS
scores than there were subject with DCI at PBD30; however, this difference was not seen
at PBD90. There were also no significant differences in the percentage of subjects with
good GOSE scores between subjects with and without DCI at both PBD30 and PBD90.
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Table 9: Biobank Subject mRS and GOSE Scores by DCV Status

Good mRS-PBD30

No DCV

DCV

p-value

(N=14)

(N=11)

8 (57.1%)

5 (45.4%)

0.193

12 (85.7%)

8 (72.7%)

0.385

6 (42.9%)

2 (18.2%)

0.076

11 (78.6%)

8 (72.7%)

0.772

(Scores = 0-3)
Good mRS-PBD90
(Scores = 0-3)
Good GOSE-PBD30
(Scores = 5-8)
Good GOSE-PBD90
(5cores = 5-8)
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Table 10: Biobank Subject mRS and GOSE Scores by DCI Status

Good mRS-PBD30

No DCI

DCI

p-value

(N=18)

(N=7)

11 (73.3%)

2 (28.6%)

0.047

15 (88.2%)

5 (83.3%)

0.759

7 (46.7%)

1 (14.3%)

0.141

15 (88.2%)

4 (66.7%)

0.231

(Scores 0-3)
Good mRS-PBD90
(Scores 0-3)
Good GOSE-PBD30
(Scores 5-8)
Good GOSE-PBD90
(Scores 5-8)

2.3.4 Biofluid sample collection & preparation
Biofluid samples, including plasma and CSF, were collected from all 25 research
subjects on PBD3, PBD5, and PBD7. For 1 subject, plasma and CSF samples were not
obtained on PBD10 because the subject had already been discharged alive from the
hospital. For 1 additional subject, CSF samples alone were not obtained on PBD10
because the LAR refused sampling due to significantly increased subject mental
confusion and agitation prior to sampling.

Biofluid preparation was completed according to the described protocol for all
samples. There were no samples that required more than 30 minutes to complete. After
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biofluid preparation, 594 plasma samples and 588 CSF samples were added to the
biobank. All samples were stored at -80C until used.

2.3.5 Haptoglobin phenotype analysis
The haptoglobin phenotype was determined by ELISA for all 25 patients using the
described protocol. All validation criteria were successfully met for these samples. The
OD results from the supplied control samples, the calculated optical density (OD) range
criteria, and the mean measured OD for each phenotype are described in Table 11.
Table 11: Optical Density (OD) Results from Hp Phenotype Analysis
Control OD

Calculated OD

Mean (SD)

measurement

range for Hp

measured OD of

phenotype

biobank samples

Blank

0.053 (0.002)

NA

NA

Hp1-1

0.063 (0.010)

<0.2

0.105 (0.082)

Hp1-2

0.482 (0.011)

0.2 – 0.936

0.570 (0.135)

Hp2-2

1.561 (0.006)

>0.936

2.231 (0.366)

There were 3 subjects (12%) identified as Hp1-1, 14 subjects (56%) identified as
Hp1-2, and 8 subjects (32%) identified as Hp2-2 from this analysis. An analysis of
demographic and disease-specific data, as well as, DBI diagnoses based on Hp Phenotype
are found in Table 12. There were no statistically significant differences in demographic
or disease-specific data or DBI diagnoses among subjects with different Hp phenotypes.
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Table 12: Biobank Subject Data by Hp Phenotype

Age (years)

Gender (male)

Height (cm)

Weight (kg)

Body Mass Index
(kg/m2)
Favorable HH Score
(0-3)
Favorable WFNS
Score (1-3)
Modified Fischer
Score (3)
Aneurysm Location

Hp1-1

Hp1-2

Hp2-2

(N=3)

(N=14)

(N=8)

49

63

66

(48 – 51)

(49 – 67)

(53 – 77)

2

6

2

(66.7%)

(42.9%)

(25.0%)

170.1

167.6

163.9

(167.6 –

(162.5 –

(161.2 –

177.8)

173.9)

177.8)

93.5

92.0

100.2

(85.3 – 122.8)

(73.5 – 107.1)

(65.9 – 115.0)

34.3

31.6

34.8

(30.5 – 39.3)

(28.1 – 34.0)

(24.9 – 38.4)

2

11

7

(66.7%)

(78.6%)

(87.5%)

2

10

5

(66.7%)

(71.4%)

(62.5%)

1

7

3

(33.3%)

(50.0%)

(37.5%)

3

8

5
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p-value

0.476

0.430

0.589

0.823

0.787

0.729

0.910

0.787

NA

(Anterior)

(100.0%)

(57.1%)

(62.5%)

3

14

7

(100.0%)

(100.0%)

(87.5%)

DCV

2

7

2

(Yes)

(66.7%)

(50.0%)

(25.0%)

DCI

1

4

2

(Yes)

(33.3%)

(28.6%)

(25.0%)

1

1

0

(33.3%)

(7.1%)

(0.0%)

Obliteration Therapy
(Coiled)

Cerebral Infarction
(Yes)

NA

0.367

0.961

NA

There were 17 subjects (68%) identified as Hp1 and 8 subjects (32%) identified as
Hp2 in this research study. An analysis of demographic and disease-specific data, as
well as, DBI diagnoses based on Hp Class are found in Table 13. There were no
statistically significant differences in demographic or disease-specific data or DBI
diagnoses between subjects in different Hp classes.
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Table 13: Biobank Subject Data by Hp Class
Hp1

Hp2

N=18

N=7

59

63

(48.3 – 66.5)

(52.5 – 74)

8 (44.4%)

2 (28.6%)

0.66

Height (cm)

167.6 (162.5 – 173.9)

165.1 (162.6 – 177.8)

0.93

Weight (kg)

89.8 (71.8 – 107.1)

114.1 (76.1 – 115.1)

0.43

Body Mass Index

31.6 (26.9 – 34.2)

36.4 (29.1 – 39.7)

0.47

16 (88.9%)

6 (85.7%)

1.00

12 (66.7%)

5 (71.4%)

1.00

10 (55.6%)

4 (57.1%)

1.00

11 (61.1%)

5 (71.4%)

1.00

18 (100.0%)

6 (85.7%)

0.28

9 (50%)

2 (28.6%)

0.41

Age (years)

Gender (male)

p-value

0.76

(kg/m2)
Favorable HH Score
(0-3)
Favorable WFNS
Score (0-3)
Modified Fischer
Score (4)
Aneurysm Location
(Anterior)
Obliteration Therapy
(Coiled)
Delayed Cerebral
Vasospasm
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Delayed Cerebral

5 (27.8%)

2 (28.6%)

1.00

2 (11.1%)

0 (0.0%)

1.00

Ischemia
Delayed Cerebral
Infarction

2.3.6 Subject safety analysis
Subject safety data was recorded for all 25 subjects enrolled in this study. One
subject (4%) developed bacteremia approximately 1 week after the final plasma sample.
This is consistent with the historical rate of bacteremia after aSAH at the University of
Kentucky. This infection was treated successfully with antibiotics and there were no
apparent sequelae from this infection. After review with the attending neurosurgeons,
this infection was not thought to be related to study sampling procedures.

Two subjects (8%) developed ventriculitis during study involvement. This is
consistent with the historical rate of ventriculitis after aSAH at the University of
Kentucky. These infections were treated successfully with antibiotics and there were no
apparently sequelae from these infections. After review with the attending
neurosurgeon, neither infection was thought to be related to study sampling procedures.

Three additional subjects (12%) required replacement of their EVD during study
involvement. This is consistent with the historical rate of EVD replacement after aSAH
at the University of Kentucky. After review with the attending neurosurgeons, none of
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these cases was deemed to be related to CSF sampling for this study as all three patients
had significant hemorrhage burden, likely resulting in catheter or drainage tubing
thrombosis.

There were no known breaches of confidentiality or other safety concerns during
this study period.

2.4 Conclusions
This chapter described the successful development of a prospective aSAH
biobank at the University of Kentucky Chandler Medical Center. Over 2 years of
subject recruitment, 25 subjects were enrolled in the biobank. Demographic, clinical and
outcome data, as well as, biofluid samples at multiple time points were obtained from
each patient and are available, upon request, for future research. This biobank will allow
future research to investigate causes, interactions and outcomes of DBI in aSAH patients.
Two of these studies are described in the following chapters.

CHAPTER 3: INFLAMMATORY CYTOKINE ANALYSIS IN PATIENTS WITH
ANEURYSMAL SUBARACHNOID HEMORRHAGE
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3.1 Introduction
This chapter focuses on an analysis of plasma and CSF concentrations of 3
inflammatory cytokines, IL-1β, IL-6 and TNF-α, at multiple time points in patients with
aneurysmal subarachnoid hemorrhage (aSAH). Previous studies have demonstrated a
relationship between these cytokines and the risk of delayed brain injuries (DBI) after
aSAH. I have, therefore, hypothesized that these inflammatory cytokines are central in
the immune-mediated model of DBI after aSAH. To investigate this hypothesis, the
aims of this study, therefore, were to measure plasma and cerebrospinal fluid (CSF) IL1β, IL-6 and TNF-α concentrations at multiple time points after aSAH and evaluate
whether there was a correlation between the concentrations of these inflammatory
cytokines and the incidence of delayed brain injuries (DBI) among aSAH subjects with
different Hp phenotypes.

3.2 Methods
3.2.1 Study design
This was a prospective cohort study using prospectively collected clinical data
and biofluid samples from a single-center aSAH biobank at the University of Kentucky
Chandler Medical Center, as well as, control subjects from the University of Kentucky
CCTS Research Registry and Specimen Bank.
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3.2.2 Study population
Demographic, disease-specific and outcome data, as well as, biofluid samples
from post-bleed day 3 (PBD3), PBD5, PBD7 and PBD10 were included from all subjects
in the aSAH biobank. The details of the collection, preparation and storage of the data
and samples in this biobank are described in Chapter 2. Biobank subjects were excluded
if there was missing demographic or disease-specific data, if the presence or absence of
DBI diagnoses were not defined, or if biofluid samples from PBD3, PBD5, or PBD7
were not drawn or were missing.

Control samples were obtained from The University of Kentucky Center for
Clinical and Translation Science Research Registry and Specimen Bank. This specimen
bank contains samples from more than 34,000 patients and includes more than 1400
plasma and 80 CSF samples. Samples in this registry were obtained, according to an
IRB-approved protocol, and subjects provided informed consent for their involvement in
this specimen bank. For this study, biofluid samples were obtained from all patients in
this registry who had both blood and CSF samples obtained within 24 hours of each
other. Biofluid samples were not obtained from patients with hemorrhagic stroke,
ventriculitis, meningitis, and human immunodeficiency virus (HIV), hepatitis B, and
hepatitis C infections.
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3.2.3 Biofluid cytokine analysis
After IRB approval, plasma and CSF samples from all 25 subjects in the aSAH
biobank and 9 control subjects were identified for cytokine analysis. Samples from
PBD3, PBD5, PBD7 and PBD10 were selected for subjects in the aSAH biobank, when
available. Quantitative cytokine analysis (IL-6, IL-1β, and TNF-α) was performed by
the University of Kentucky Center for Clinical and Translation Research (CCTS)
Bioanalysis Lab (BAL) using a commercial kit (V-PLEX Human Proinflammatory Panel
I) manufactured by Meso Scale Diagnostics (Rockville, MD) (Catalog # K15052D, Lot #
K0081080, Exp 1/31/2021; Lot # K0031225, Exp 3/31/2021; Lot # K0031225, Exp
3/31/2021; Lot # K0081189, Exp 3/31/2021). This kit contains 96-well multi-spot
ELISA plates, control and calibrator samples for target cytokines, and other
miscellaneous supplies needed to complete the analysis. This kit was chosen because it
has been validated in both plasma and CSF and has a high reported accuracy for the
target concentrations of these cytokines.205,206

Cytokine concentrations were determined using the MESO Quickplex SQ 120
Multiplex plate reader (Meso Scale Diagnostics, Rockville, MD). Standard curves for
each cytokine were constructed using a log-log curve-fit from calibrator samples. Target
cytokine concentrations were measured twice for each sample and the results were
averaged to determine the calculated final concentration. For cytokine concentrations
that were below the lower limit of detection (LLOD) or those with no-reading, the LLOD
was used as the measured cytokine concentration. For cytokine concentrations that were
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above the upper limit of detection (ULOD), the ULOD was used as the cytokine
concentration.

3.2.4 Data management plan
A data management plan was created and approved by the IRB prior to studyrelated procedures. All biobank data was copied from the biobank’s online REDCap
database directly into a separate REDCap database for this analysis. Results of the
cytokine analyses for each subject were entered into this separate REDCap database. All
cytokine data entry was verified by the PI. All data errors were immediately corrected in
the online database by the PI.

3.2.5 Statistical analysis plan
A statistical analysis plan was created in consultation with a statistician from the
University of Kentucky Applied Statistics Lab. All categorical and ordinal data are
reported as count and percentage. Continuous data distributions that met the
assumptions for normalized data are described by mean and standard deviation (SD).
Continuous data distributions that did not meet the assumptions for normalized data are
reported as median and interquartile range (IQR). For tables and analyses with mixed
normal and non-normal data distributions, all data are described by median and IQR.

The Fischer’s Exact or Pearson Chi-Squared tests were used, as appropriate, for
hypothesis testing involving categorical or ordinal data. The two-tailed t-test, the
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Independent Samples Mann-Whitney U Test, or the Independent Samples Kruskal-Wallis
Test was used for hypothesis testing involving normal and non-normal continuous data.
respectively. For all hypothesis testing, a p-value <0.05 was considered significant. All
statistical analyses were completed with IBM SPSS version 25 (IBM Corp, Armonk,
NY).

3.3 Results
3.3.1 Study recruitment
After IRB approval, demographic, disease-specific and outcome data, as well as,
biofluid samples from 24 subjects in the UK aSAH Biobank were used in this analysis.
One subject in the biobank was excluded after cytokine analysis and the subject’s data
was not included in demographic and inflammatory cytokine analysis. This subject was
excluded because he had ventriculitis diagnosed after consent and initial sampling
procedures that may have resulted in increased CSF and/or plasma cytokine
concentrations.

In addition, there were 9 patients in The University of Kentucky Center for
Clinical and Translation Science Research Registry and Specimen Bank that met
inclusion and exclusion criteria as previously outlined. Frozen plasma and CSF samples
from these patients were used as controls in this analysis.
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3.3.2 Demographic, delayed brain injury, and clinical outcome analysis
Baseline demographic and disease-specific data for all subjects in the biobank is
summarized in Table 14.
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Table 14: Subject Demographic and Disease-Specific Data for Cytokine Analyses
Results
N=24
Age (years)

63 (51 – 70)

Gender (male)

9 (37.5%)

Height (cm)

167.6 (162.5 – 175.9)

Weight (kg)

89.9 (69.7 – 113.7)

Body Mass Index (kg/m2)

33.5 (26.6 – 37.4)

Good Hunt Hess Score (1-3)

20 (87.5%)

Good WFNS Score (1-3)

17 (70.8%)

Good Modified Fischer Score (1-3)

10 (41.7%)

Aneurysm Location (Anterior)

15 (62.5%)

Obliteration Therapy (Coiled)

23 (95.8%)

Ten subjects (42%) developed DCV, 7 subjects (29.2%) developed DCI, and 2
subjects (8.3%) developed delayed cerebral infarction after aSAH. There were no
statistically significant differences in demographic and disease-specific data between
subjects with and without DCV or DCI.

Of the 24 study subjects, 22 subjects (92%) survived to hospital discharge. One
patient died after PBD14 due to withdrawal of life-supporting care after spontaneous
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rupture of a second aneurysm and 1 patient died after PBD10 due to withdrawal of lifesupporting care after repeated episodes of DCV and continued poor neurologic status.

3.3.3 Inflammatory cytokine analysis
The results of plasma and CSF inflammatory cytokine analyses for the 9 control
subjects are described in Table 15. Table 16 and Table 17 describe the results of plasma
and CSF inflammatory cytokine analyses, respectively, for study subjects by PBD. An
analysis of the differences between cytokine concentrations in control and study subjects
demonstrated that at all time points, the median plasma IL-1β concentration of the
research subjects was significantly less than the median of the control subjects, the CSF
IL-1β concentration of the research subjects was significantly greater than in the control
subjects, the plasma IL-6 concentration was not significantly different from the control
subjects, the CSF IL-6 concentration of the research subjects was significantly greater
than in control subjects, the plasma TNF-α concentration of the research subjects was
significantly less than in the control subjects, and the CSF TNF-α concentration of the
research subjects was significantly greater than in the control subjects.
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Table 15: Results of Inflammatory Cytokine Analysis for Control Subjects

IL-1β (pcg/mL)

IL-6 (pcg/mL)

TNF-α (pcg/mL)

Plasma

CSF

(N=9)

(N=9)

0.80

0.02

(0.48 – 2.14)

(0.01 – 0.04)

4.97

2.75

(3.35 – 9.71)

(2.45 – 9.66)

3.55

0.33

(2.93 – 6.44)

(0.31 – 0.35)

Table 16: Results of Plasma Inflammatory Cytokine Analysis for all Study Subjects

IL-1β
(pcg/mL)
IL-6
(pcg/mL)
TNF-α
(pcg/mL)

PBD3

PBD5

PBD7

PBD10

(N=24)

(N=24)

(N=24)

(N=22)

0.08

0.13

0.13

0.12

(0.05 – 0.17)

(0.07 – 0.19)

(0.05 – 0.16)

(0.08 – 0.14)

7.87

5.70

4.28

3.77

(3.02 – 12.36)

(3.46 – 11.22)

(2.86 – 7.59)

(2.54 – 9.20)

2.06

2.50

2.40

2.56

(1.49 – 2.57)

(2.12 – 2.64)

(2.13 – 2.64)

(2.29 – 3.10)
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Table 17: Results of CSF Inflammatory Cytokine Analysis for all Study Subjects

IL-1β
(pcg/mL)
IL-6
(pcg/mL)

TNF-α
(pcg/mL)

PBD3

PBD5

PBD7

PBD10

(N=24)

(N=24)

(N=24)

(N=23)

0.83

2.50

1.18

0.98

(0.31-1.81)

(1.66 – 3.43)

(0.57 – 2.45)

(0.52 – 1.69)

203.18

2033.34

1569.99

610.74

(103.21 –

(1189.13 –

(945.52 –

(270.84 –

578.85)

2232.33)

1952.51)

880.28)

1.60

3.76

2.10

1.60

(0.87 – 3.25)

(2.08 – 4.92)

(1.45 – 4.31)

(1.24 – 2.83)

3.3.4 Inflammatory cytokine analysis by delayed brain injury status
The results of plasma and CSF inflammatory cytokine analysis of study subjects,
categorized by DCV and DCI status are shown in Figures 11 and 12, respectively. There
were no statistically significant differences in either plasma or CSF IL-1β, IL-6 or TNF-α
concentrations between study subjects with and without DCV or DCI at any time point.
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Figure 11: Plasma and CSF Cytokine Concentrations by DCV Status

In this experiment, cytokine concentrations in plasma and cerebrospinal fluid (CSF) were
determined at multiple pre-defined time points by ELISA from 24 subjects with
aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by their delayed cerebral vasospasm (DCV) status. There
were no statistically significant differences at any time points in any of the cytokine
concentrations in plasma or CSF between subjects with and without DCV.
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Figure 12: Plasma and CSF Cytokine Concentrations by DCI Status

In this experiment, cytokine concentrations in plasma and cerebrospinal fluid (CSF) were
determined at multiple pre-defined time points by ELISA from 24 subjects with
aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by their delayed cerebral ischemia (DCI) status. There were
no statistically significant differences at any time points in any of the cytokine
concentrations in plasma or CSF between subjects with and without DCI.
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3.3.5 Inflammatory cytokine analysis by haptoglobin phenotype
The results of plasma and CSF inflammatory cytokine analysis of study subjects,
categorized by Hp phenotype and Hp class are shown in Figures 13 and 14, respectively.
There were no statistically significant differences in either plasma or CSF IL-1β, IL-6 or
TNF-α concentrations between study subjects with different Hp phenotype or Hp class at
any time point.

The results of plasma and CSF inflammatory cytokine analysis of study subjects,
categorized by both Hp class and DCV and DCI status are shown in Figures 15 and 16,
respectively. There were no statistically significant differences in either plasma or CSF
IL-1β, IL-6 or TNF-α concentrations between these groupings of study subjects at any
time point.
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Figure 13: Plasma and CSF Cytokine Concentrations by Hp Phenotype

In this experiment, cytokine concentrations in plasma and cerebrospinal fluid (CSF) were
determined at multiple pre-defined time points by ELISA from 24 subjects with
aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by their haptoglobin (Hp) phenotype. There were no
statistically significant differences at any time points in any of the cytokine
concentrations in plasma or CSF between subjects based on their Hp phenotype.

93

Figure 14: Plasma and CSF Cytokine Concentrations by Hp Class

In this experiment, cytokine concentrations in plasma and cerebrospinal fluid (CSF) were
determined at multiple pre-defined time points by ELISA from 24 subjects with
aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by their haptoglobin (Hp) class. There were no statistically
significant differences at any time points in any of the cytokine concentrations in plasma
or CSF between subjects based on their Hp class.
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Figure 15: Plasma and CSF Cytokine Concentrations Hp Class and DCV Status

In this experiment, cytokine concentrations in plasma and cerebrospinal fluid (CSF) were
determined at multiple pre-defined time points by ELISA from 24 subjects with
aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by a combination of their haptoglobin (Hp) class and
delayed cerebral vasospasm (DCV) status. There were no statistically significant
differences at any time points in any of the cytokine concentrations in plasma or CSF
between subjects in different combinations of Hp class and DCV.
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Figure 16: Median Cytokine Concentrations by Hp Class and DCI Status

In this experiment, cytokine concentrations in plasma and cerebrospinal fluid (CSF) were
determined at multiple pre-defined time points by ELISA from 24 subjects with
aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by a combination of their haptoglobin (Hp) class and
delayed cerebral ischemia (DCI) status. There were no statistically significant differences
at any time points in any of the cytokine concentrations in plasma or CSF between
subjects in different combinations of Hp class and DCI.
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3.4 Conclusions
This chapter described the successful analysis of inflammatory cytokines from
plasma and CSF samples in aSAH subjects recruited to a biobank. This analysis was
performed to evaluate the effect that different Hp phenotypes have on key inflammatory
cytokines in patients with DBI after aSAH. Unfortunately, there were no significant
differences detected in these inflammatory cytokines with regard to DBI, Hp phenotypes,
or combinations of these outcomes. The implications, limitations and a description of
potential future directions for future research from this analysis will be further discussed
in Chapter 5.
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CHAPTER 4: SOLUBLE CD163 (sCD163) ANALYSIS IN PATIENTS WITH
ANEURYSMAL SUBARACHNOID HEMORRHAGE

4.1 Introduction
This chapter describes an analysis of soluble CD163 (sCD163) concentrations, in
both plasma and cerebrospinal fluid (CSF) at multiple, pre-defined time points in patients
with aneurysmal subarachnoid hemorrhage (aSAH). sCD163 is a soluble form of the
macrophage CD163 receptor that is created from enzymatic cleavage of a portion of the
macrophage CD163 receptor from the macrophage cell membrane by
ADAM17/TACE.172,173 sCD163 has been associated with several systemic diseases
associated with deranged inflammation, including sepsis, hemophagocytic syndrome,
liver failure, and disseminated intravascular coagulation (DIC).179-184 In these
conditions, a significant increase in sCD163 concentration is also correlated with a worse
prognosis.185-187 sCD163 has also been investigated in several neuroinflammatory
diseases, including multiple sclerosis, infectious encephalopathy, and chronic
inflammatory demyelinating polyneuropathy.188-190 Because of theses associations to
systemic and neuroinflammatory disease, I have hypothesized that sCD163 is an
important modifier in the immune-mediated model of DBI after aSAH. To investigate
this hypothesis, the aims of this study, therefore, were to measure plasma and
cerebrospinal fluid (CSF) sCD163 concentrations at multiple time points after aSAH and
evaluate whether there was a correlation between elevations in sCD163 and the incidence
of delayed brain injuries (DBI) among aSAH subjects with different Hp phenotypes.
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4.2 Methods
4.2.1 Study design
This was a cohort study using prospectively collected clinical data and biofluid
samples from a single-center aSAH biobank at the University of Kentucky Chandler
Medical Center, as well as, control subjects from the University of Kentucky CCTS
Research Registry and Specimen Bank.

4.2.2 Study population
Demographic, disease-specific and outcome data, as well as, biofluid samples
from post-bleed day 3 (PBD3), PBD5, PBD7 and PBD10 were included from all subjects
in the aSAH biobank. The details of the collection, preparation and storage of the data
and samples in this biobank are described in Chapter 2. For this study, biobank subjects
were excluded if there was missing demographic or disease-specific data, if the presence
or absence of DBI diagnoses were not defined, or if biofluid samples from either (postbleed day) PBD3, PBD5, or PBD7 were not drawn or were missing.

Control samples were obtained from The University of Kentucky Center for
Clinical and Translation Science Research Registry and Specimen Bank similar to the
previous description in Chapter 3.
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4.2.3 Biofluid sCD163 analysis
After IRB approval, plasma and CSF samples from all subjects in the aSAH biobank
and 9 control subjects were identified for sCD163 concentration analysis. Samples from
PBD3, PBD5, PBD7 and PBD10 were selected for subjects in the aSAH biobank, when
available. sCD163 analysis was performed by the University of Kentucky Center for
Clinical and Translation Research (CCTS) Bioanalysis Lab (BAL) using a commercial
kit manufactured by R&D Systems (Minneapolis, MN) (Catalog # DC1630, Lot #
P242744, Exp. 10/29/2021). This kit contains 96-well multi-spot ELISA plates, control
and calibrator samples for sCD163, and other miscellaneous supplies needed to complete
the analysis. This kit was chosen because it has been validated in both plasma and CSF
and has a high reported accuracy for the target concentrations of these cytokines.175,207

sCD163 concentrations were determined from the measured optical density (OD) of
prepared samples using a microplate reader set to 450 nm with wavelength correction set
to 540nm. A standard curve using a log-log curve-fit from calibrator samples was then
constructed and the OD of each sample was correlated to sCD163 concentration.
sCD163 concentrations were measured twice for each sample and the results were
averaged to determine the calculated final concentration. For sCD163 concentrations
that were below the lower limit of detection (LLOD) or those with no-reading, the LLOD
was used as the measured sCD163 concentration. For sCD163 concentrations that were
above the upper limit of detection (ULOD), the ULOD was used as the sCD163
concentration.
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4.2.4 Data management plan
A data management plan was created and approved by the IRB prior to studyrelated procedures, similar to the plan described in Chapter 3.

4.2.5 Statistical analysis plan
A statistical analysis plan was created in consultation with a statistician from the
University of Kentucky Applied Statistics Lab, similar to the plan described in Chapter 3.

4.3 Results
4.3.1 Study recruitment
After IRB approval, all 25 subjects in the aSAH biobank were included in this
study. Demographic, disease-specific and clinical data, as well as, biofluid samples
from all 25 subjects in the UK aSAH Biobank were used in this analysis. Also, as
described in Chapter 3, there were 9 control subjects that met the inclusion and exclusion
criteria. Frozen plasma and CSF samples from these subjects were obtained and used in
this study.

4.3.2 Demographic, delayed brain injury, and clinical outcome analysis
Baseline demographic and disease-specific data for all subjects in the biobank is
summarized in Table 18.
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Table 18: Subject Demographic and Disease-Specific Data for sCD163 Analyses
Results
N=25
Age (years)

63 (49-66)

Gender (male)

10 (40%)

Height (cm)

167.6 (162.5 – 177.8)

Weight (kg)

93.5 (70.0 – 113.6)

Body Mass Index (kg/m2)

33.2 (26.6 – 37.1)

Good Hunt Hess Score (0-3)

22 (88%)

Good WFNS Score (0-3)

17 (68%)

Good Fischer Score (1-3)

9 (36%)

Aneurysm Location (Anterior)

16 (64%)

Obliteration Therapy (Coiled)

24 (96%)

Eleven subjects (44%) developed DCV, 7 subjects (28%) developed DCI, and 2
subjects (8%) developed Delayed Cerebral Infarction. There were no statistically
significant differences in demographic and disease-specific data between subjects with
and subjects without any of these DBI.

Of the 25 study subjects, 23 subjects (92%) survived to discharge and 2 subjects
(8%) died prior to hospital discharge. One patient died after PBD10 due to withdrawal
of life-supporting care after repeated episodes of DCV and continued poor neurologic
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status and the other subject died after PBD14 due to withdrawal of life-supporting care
after spontaneous rupture of a second aneurysm.

4.3.3 sCD163 concentration analysis
The sCD163 concentration analysis was completed for all 25 subjects. sCD163
concentrations were determined for 108 plasma samples (99 subject samples and 9
control samples) and 107 CSF samples (98 subject samples and 9 control samples).
Plasma samples were not available for 1 study subject at PBD10 and CSF samples were
not available for 2 study subjects at PBD10. The median and IQR plasma and CSF
concentrations for the entire group of aSAH subjects were 509.3 pcg/mL (395.1 – 702.1)
and 347.9 pcg/mL (211.9 – 513.1), respectively. The median and IQR of the plasma and
CSF sCD163 concentrations for the 9 control subjects were 686.0 pcg/mL (570.2 –
923.9) and 56.2 pcg/mL (45.2 – 78.0), respectively. Table 19 describes the median and
IQR for the plasma and CSF sCD163 concentrations in aSAH subjects according to PBD.
The median plasma sCD163 concentration of the aSAH subjects was non-significantly
less than in the control subjects at all time points. The CSF sCD163 concentrations in
aSAH subjects were significantly greater than in control subjects at all time points.
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Table 19: Plasma and CSF sCD163 Concentrations in All Study Subjects
Plasma (pcg/mL)

CSF (pcg/mL)

PBD3

394.1 (358.4 – 595.8)

268.5 (143.4 – 347.9)

PBD5

500.9 (413.9 – 676.2)

456.6 (287.0 – 625.0)

PBD7

466.7 (399.9 – 696.5)

409.0 (286.4 – 537.4)

PBD10

556.4 (433.3 – 928.0)

339.1 (158.2 – 502.5)

4.3.4 sCD163 analysis by delayed brain injury status
Figures 17 and 18 illustrate the plasma and CSF median sCD163 concentrations,
respectively, at multiple time points according to subject DCV status. Although the
median plasma sCD163 concentration was less in subjects with DCV than in those
without DCV at all time points, these differences were not statistically significant. There
were no significant differences in the CSF sCD163 concentration between subjects with
and without DCV at any time points.
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Figure 17: Plasma sCD163 in aSAH Subjects Grouped by DCV Status

In this experiment, the soluble CD163 (sCD163) concentration in plasma was determined
at multiple pre-defined time points by ELISA from 25 subjects with aneurysmal
subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank. These subjects
were grouped by their delayed cerebral vasospasm (DCV) status. The bars represent the
median sCD163 concentrations for each group at each time point; whereas, the individual
markings represent the measured sCD163 concentrations for each subject at each time
point. Although the median plasma sCD163 concentrations were less in subjects with
DCV at all time points, these differences were not statistically significant.
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Figure 18: CSF sCD163 in aSAH Subjects Grouped by DCV Status

In this experiment, the soluble CD163 (sCD163) concentration in cerebrospinal fluid
(CSF) was determined at multiple pre-defined time points by ELISA from 25 subjects
with aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by their delayed cerebral vasospasm (DCV) status. The
bars represent the median sCD163 concentrations for each group at each time point;
whereas, the individual markings represent the measured sCD163 concentrations for each
subject at each time point. There were no statistically significant differences in CSF
sCD163 concentrations at any time point.
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Figures 19 and 20 illustrate the median plasma and CSF sCD163 concentrations,
respectively, at multiple time points according to subject DCI status. Similar to the
findings with DCV, the median plasma sCD163 was less at multiple time points in
subjects with DCI than in subjects without DCI, although these differences were not
statistically significant. In CSF, the median sCD163 concentration was greater at all
time points in subjects with DCI than in subjects without DCI; however, the differences
were also not statistically significant.
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Figure 19: Plasma sCD163 in aSAH Subjects Grouped by DCI Status

In this experiment, the soluble CD163 (sCD163) concentration in plasma was determined
at multiple pre-defined time points by ELISA from 25 subjects with aneurysmal
subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank. These subjects
were grouped by their delayed cerebral ischemia (DCI) status. The bars represent the
median sCD163 concentrations for each group at each time point; whereas, the individual
markings represent the measured sCD163 concentrations for each subject at each time
point. Although the median plasma sCD163 concentrations were less in subjects with
DCI at all time points, these differences were not statistically significant.
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Figure 20: CSF sCD163 in aSAH Subjects Grouped by DCI Status

In this experiment, the soluble CD163 (sCD163) concentration in cerebrospinal fluid
(CSF) was determined at multiple pre-defined time points by ELISA from 25 subjects
with aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by their delayed cerebral ischemia (DCI) status. The bars
represent the median sCD163 concentrations for each group at each time point; whereas,
the individual markings represent the measured sCD163 concentrations for each subject
at each time point. Although the median CSF sCD163 concentrations were greater in
subjects with DCI at all time points, these differences were not statistically significant.
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4.3.5 sCD163 analysis by haptoglobin phenotype and haptoglobin class
The median plasma and CSF sCD163 concentrations at PBD3, PBD5, PBD7 and
PBD10 between subjects with different haptoglobin phenotype (Hp1-1, Hp1-2, and Hp22) are shown in Figure 21 and Figure 22, respectively. The median plasma sCD163
concentration was greater at all time points in Hp2-2 subjects than in Hp1-1 and Hp1-2
subjects; however, these differences were not statistically significant. In CSF, there was
no clear association between the Hp phenotype and the median sCD163 concentrations at
any time point.
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Figure 21: Plasma sCD163 in aSAH Subjects Grouped by Hp Phenotype

In this experiment, the soluble CD163 (sCD163) concentration in plasma was determined
at multiple pre-defined time points by ELISA from 25 subjects with aneurysmal
subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank. These subjects
were grouped by their haptoglobin (Hp) phenotype. The bars represent the median
sCD163 concentrations for each group at each time point; whereas, the individual
markings represent the measured sCD163 concentrations for each subject at each time
point. Although the median plasma sCD163 concentrations was greatest in Hp2-2
subjects at all time points, these differences were not statistically significant.
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Figure 22: CSF sCD163 in aSAH Subjects Grouped by Hp Phenotype

In this experiment, the soluble CD163 (sCD163) concentration in cerebrospinal fluid
(CSF) was determined at multiple pre-defined time points by ELISA from 25 subjects
with aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by their haptoglobin (Hp) phenotype. The bars represent
the median sCD163 concentrations for each group at each time point; whereas, the
individual markings represent the measured sCD163 concentrations for each subject at
each time point. There were no statistically significant differences in CSF sCD163
concentrations by Hp phenotype at any time point.
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The median plasma and CSF sCD163 concentrations at PBD3, PBD5, PBD7 and
PBD10 by haptoglobin class (Hp1 and Hp2) are shown in Figures 23 and 24,
respectively. Similar to the findings in the Hp phenotype analysis, the median plasma
sCD163 concentration was greater in the Hp2 subjects than in the Hp1 subjects at all time
points; however, these differences were not statistically significant. In CSF, there were
no statistically significant differences in the sCD163 concentrations between the Hp
classes at any of the time points.
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Figure 23: Plasma sCD163 in aSAH Subjects Grouped by Hp Class

In this experiment, the soluble CD163 (sCD163) concentration in plasma was determined
at multiple pre-defined time points by ELISA from 25 subjects with aneurysmal
subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank. These subjects
were grouped by their haptoglobin (Hp) class. The bars represent the median sCD163
concentrations for each group at each time point; whereas, the individual markings
represent the measured sCD163 concentrations for each subject at each time point.
Although the median plasma sCD163 concentrations was greatest in Hp2 subjects at all
time points, these differences were not statistically significant.
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Figure 24: CSF sCD163 in aSAH Subjects Grouped by Hp Class

In this experiment, the soluble CD163 (sCD163) concentration in cerebrospinal fluid
(CSF) was determined at multiple pre-defined time points by ELISA from 25 subjects
with aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by their haptoglobin (Hp) class. The bars represent the
median sCD163 concentrations for each group at each time point; whereas, the individual
markings represent the measured sCD163 concentrations for each subject at each time
point. There were no statistically significant differences in sCD163 concentration by Hp
class at any time point.
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The median plasma and CSF sCD163 concentrations at PBD3, PBD5, PBD7 and
PBD10 by haptoglobin class (Hp1 and Hp2) and DBI (both DCV and DCI) are shown in
Figures 25-28. Although the plasma sCD163 concentration was greatest in the Hp2
subjects without DCV than in other groups, this was statistically significant compared to
the Hp2 subjects with DCV at both PBD3 and PBD5. There was no trend or statistical
significance between the combination of Hp class and DCV in CSF.

Likewise, there

were no significant trends or statistically significant differences in either the plasma or
CSF sCD163 concentrations between the combination of Hp classes and DCI at all time
points.
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Figure 25: Plasma sCD163 in aSAH Subjects Grouped by Hp Class and DCV Status

In this experiment, the soluble CD163 (sCD163) concentration in plasma was determined
at multiple pre-defined time points by ELISA from 25 subjects with aneurysmal
subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank. These subjects
were grouped by a combination of their haptoglobin (Hp) class and delayed cerebral
vasospasm (DCV) status. The bars represent the median sCD163 concentrations for
each group at each time point; whereas, the individual markings represent the measured
sCD163 concentrations for each subject at each time point. There was a statistically
significant difference the sCD163 concentration between Hp2 subjects with and without
DCV at PBD3 and PBD5. At other time points, there is a non-significant difference
between the Hp2 subjects with and without DCV. There were no differences in Hp1
subjects with and without DCV at all time points.
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Figure 26: CSF sCD163 in aSAH Subjects Grouped by Hp Class and DCV Status

In this experiment, the soluble CD163 (sCD163) concentration in cerebrospinal fluid
(CSF) was determined at multiple pre-defined time points by ELISA from 25 subjects
with aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by a combination of their haptoglobin (Hp) class and
delayed cerebral vasospasm (DCV) status. The bars represent the median sCD163
concentrations for each group at each time point; whereas, the individual markings
represent the measured sCD163 concentrations for each subject at each time point.
There were no statistically significant differences in any of the defined groups at any time
point.
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Figure 27: Plasma sCD163 in aSAH Subjects Grouped by Hp Class and DCI Status

In this experiment, the soluble CD163 (sCD163) concentration in plasma was determined
at multiple pre-defined time points by ELISA from 25 subjects with aneurysmal
subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank. These subjects
were grouped by a combination of their haptoglobin (Hp) class and delayed cerebral
ischemia (DCI) status. The bars represent the median sCD163 concentrations for each
group at each time point; whereas, the individual markings represent the measured
sCD163 concentrations for each subject at each time point. There were no statistically
significant differences in any of the defined groups at any time point.

119

Figure 28: CSF sCD163 in aSAH Subjects Grouped by Hp Class and DCI Status

In this experiment, the soluble CD163 (sCD163) concentration in cerebrospinal fluid
(CSF) was determined at multiple pre-defined time points by ELISA from 25 subjects
with aneurysmal subarachnoid hemorrhage (aSAH) in a prospectively-collected biobank.
These subjects were grouped by a combination of their haptoglobin (Hp) class and
delayed cerebral ischemia (DCI) status. The bars represent the median sCD163
concentrations for each group at each time point; whereas, the individual markings
represent the measured sCD163 concentrations for each subject at each time point.
There were no statistically significant differences in any of the defined groups at any time
point.
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4.4 Conclusions
This chapter described the successful analysis of sCD163 from plasma and CSF
samples in aSAH subjects recruited to a biobank. This analysis was performed to
evaluate the effect that different Hp phenotypes have on sCD163 concentration to assess
their influential role in the development of DBI after aSAH. Although there were few
statistically significant differences in the primary analyses, there are multiple nonsignificant differences and trends that may warrant additional research with more patients
to detect significant differences in the groups. These differences will lead to a better
understanding of the potential mechanisms that explain the mediator function of Hp
phenotypes and inflammation in DBI after aSAH. The implications, limitations and
future directions from this analysis will be further discussed in Chapter 5.
.
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CHAPTER 5: CONCLUSIONS

5.1 Introduction
This chapter summarizes the key findings, implications, limitations and future
direction with regard to the effects of different haptoglobin phenotypes on delayed brain
injuries (DBI) after aneurysmal subarachnoid hemorrhage (aSAH). aSAH, a form of
hemorrhagic stroke, is associated with significant mortality and morbidity related DBI
that occur more than 72 hours after the onset of aSAH, namely delayed cerebral
vasospasm (DCV) and delayed cerebral ischemia (DCI). Recently, observational
clinical data have correlated the incidence and outcome of DBI with different haptoglobin
(Hp) phenotypes through an unknown mechanism. For this reason, previous chapters
have described the development of an aSAH biobank at the University of Kentucky to
facilitate current and future observational research in aSAH (chapter 2) and, using this
biobank, two different potential mechanisms, altered systemic or CSF cytokine (chapter
3) expression and differential soluble CD163 (sCD163) (chapter 4) expression have been
explored.

5.2 Key Findings
5.2.1 Key findings from the development of the UK aSAH biobank
During the 2-year period from July 2018 to June 2020, the UK aSAH biobank
project screened 106 patients with aSAH and successfully recruited 25 patients with
radiographically-proven aSAH. Approximately 50% of these recruited subjects
122

developed 1 or more DBI during their hospitalization. Specifically, 45% of all subjects
developed DCV, 30% developed DCI, and 10% developed delayed cerebral infarction.
Despite these findings, approximately 90% of subjects had a favorable outcome at
PBD90. This is significantly better than would be expected from the published
literature.

Plasma and CSF samples were successfully collected, processed and stored

at multiple time points, according to study protocols, for all 25 subjects. There were no
significant adverse events, data safety issues, or patient complaints directly related to the
biobank research protocols.

In addition, the Hp phenotype and Hp class were successfully determined from
stored plasma samples in all 25 subjects. There were 3 Hp1-1 patients (12%), 14 Hp1-2
patients (56%), and 8 Hp2-2 patients (32%). Likewise, there were 17 Hp1 class patients
(68%) and 8 Hp2 class patients (32%). These findings are consistent with the expected
prevalence of the Hp phenotypes and Hp classes based on the population demographics
of Kentucky. There were no significant differences in the baseline demographics or
disease-specific data between subjects with different Hp phenotypes or Hp classes.
There were also no significant differences in the percentage of subjects who developed
DBI between the different Hp phenotypes or Hp classes.

5.2.2 Key findings from the inflammatory cytokine analysis
Clinical data and biofluid samples from 24 subjects in the UK aSAH biobank and
9 control subjects from the UK CCTS Research Registry and Specimen bank were used
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to evaluate the association of three inflammatory cytokines, IL-1β, IL6, and TNF-α, and
DBI at multiple time points after aSAH. While there were significant differences in the
plasma and CSF concentrations of IL-1β, IL-6 and TNF-α between study subjects and
control subjects, there were no significant differences in any of the plasma or CSF
inflammatory cytokine concentrations when study subjects were grouped based on either
their DCV or DCI status. Likewise, there were no significant differences in any of the
plasma or CSF inflammatory cytokine concentrations when study subjects were grouped
based on either their Hp phenotype or Hp class. Finally, there were no significant
differences in any of the plasma or CSF inflammatory cytokine concentrations when
study subjects were grouped based on a combination of their Hp class and DCV status or
a combination of their Hp class and DCI.

5.2.3 Key findings from the sCD163 analysis
Clinical data and biofluid samples from 25 subjects in the UK aSAH biobank and
9 control subjects from the UK CCTS Research Registry and Specimen bank were used
in plasma and CSF analyses of sCD163 concentrations. The plasma sCD163
concentration in the study subjects was non-significantly lower than in the control
subjects, while the CSF sCD163 concentration was significantly greater in study subjects
than in the control subjects. The plasma sCD163 concentration in study subjects with
DCV was non-significantly lower than the sCD163 concentration in those without DCV.
Unfortunately, there were no differences in the CSF sCD163 concentration in study
subjects based on their DCV status. There were no differences in either the plasma or
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CSF sCD163 concentrations in study subjects based on their DCI status. The plasma
concentration of sCD163 was non-significantly greater at all time points in Hp2-2
subjects than in either Hp1-1 or Hp1-2 study subjects. Similarly, the plasma sCD163
concentration was non-significantly greater in Hp2 class subjects than in Hp1 class study
subjects. There were no differences in the CSF sCD163 concentration between subjects
based on either Hp phenotype or class. Hp2-2 subjects without DCV had a significantly
greater plasma sCD163 concentration that other subjects at PBD3 and PBD5 and nonsignificantly greater sCD163 concentration at other time points. Finally, there were no
significant differences in either the plasma or CSF sCD163 concentrations when study
subjects were grouped based a combination of their Hp class and DCI.

5.3 Implications
5.3.1 Implications of the UK aSAH biobank
There are several important implications from the UK aSAH biobank project.
First, the UK aSAH biobank project demonstrated the ability to successfully recruit
subjects early in their clinical course, to collect relevant clinical data from the EMR, and
to obtain, process and store important biofluid samples from patients admitted to the
hospital with aSAH. It was important to demonstrate this ability because enrolling and
following a complex research protocol in these patients is challenging. Patients do not
arrive to the hospital in a predictable fashion, in fact, they frequently arrive at night, on
weekends, or other times when research staff availability may be reduced. The future
development of a sustainable process to continue subject recruitment beyond this initial
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2-year period will be important to facilitate future clinical and translation research in
aSAH patients.

Second, the UK aSAH biobank project demonstrated that, despite using
conservative estimates of hospitalization and rates of exclusion criteria in the target
population, the number of subjects actually recruited during the study period was
significantly lower than was predicted. In fact, only 25% of the aSAH patients admitted
to the UK Chandler Medical Center were ultimately recruited to the study and, therefore,
the amount of data and biofluid samples available for analyses at the end of the 2-year
recruitment period was limited. This was largely due to a larger than expected number
of subjects having 1 or more of the exclusion criteria. The most frequent exclusion
criteria were subjects not receiving an EVD before PBD3, subjects having a nonsurvivable injury at the time of admission, or subjects not having family available before
PBD3. Future research should take these findings into consideration when evaluating
the feasibility of future research studies in this population.

Third, the UK aSAH biobank project demonstrated that that the Hp phenotype and
Hp class of aSAH patients can be successfully determined from stored plasma samples,
although comparing the results of these ELISA tests against the results of the more
established gel electrophoresis method may also be needed. Nevertheless, the
prevalence of the different Hp phenotypes in this study sample is similar to the predicted
distributions based on the population estimates of Kentucky with the following
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phenotype proportions: Hp1-1: 15%, Hp1-2: 55%, and Hp2-2: 30%. Likewise, the
proportion of the different Hp classes appear to be similar to the predicted distributions
from population estimates of Kentucky. These findings are important to allow for more
accurate future predictions of research feasibility in aSAH patients based on Hp
phenotype or Hp class prevalence.

5.3.2 Implications of the inflammatory cytokine analysis
The inflammatory cytokine analysis failed to provide direct evidence to support
the more complex inflammation-mediated model of DBI after aSAH. In fact, there were
no discernable differences in any of the inflammatory cytokines tests in plasma or CSF
with regard to DCV status, DCI status, or Hp phenotype. In addition, subgroup analyses
of Hp class and DBI also did not demonstrate any discernable differences in the measured
cytokine concentrations.

This study may have failed to support the advanced mechanistic model of DBI for
several reasons. First, there really may be no significant differences in the measured
inflammatory cytokine concentrations between patients with and without DBI. This
seems unlikely given the pre-existing published literature detailing cytokine
concentration differences in these populations.54,56 Second, this observation may reflect
differences in patients, treatments or other conditions at UK Chandler Medical Center
that affect cytokine concentrations differently from other medical centers. This also
seems unlikely because the baseline patient demographics were not different between
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patients with different DBI status and different Hp phenotypes and the treatments
provided to patients at UK Chandler Medical Center, based on published guidelines, are
similar, if not identical, to the treatments provided at other medical centers. Third, this
observation may have occurred because of problems or complications resulting from
either sampling/processing/storage of biofluids or from cytokine analysis. The
sampling/processing/storage of plasma and CSF were performed using standard
procedures, similar to the assay manufacturer recommendations for processing and
storage. The assay plates and supplies themselves were all purchased at the same time
and from the same manufacturing lots within 3 months of their use, were stored
according to manufacturer recommendations, and none of the supplies or plates had
reached their expiration dates at the time they were used. In addition, the measured
concentrations of the control samples used on each plate were all consistent with the
reported concentration from the manufacturer and the UK CCTS Biomarker Analysis
Laboratory (BAL) was used to perform these assays and has significant previous
experience with these assays. For these reasons, it seems unlikely that there were
significant issues with sampling/processing/storage or analysis of these inflammatory
cytokines. Fourth, there may have been important differences discovered if biofluid
samples had been obtained earlier. While, the focus of this work was injury that
occurred after PBD3, by not obtaining samples until this time point, significant
differences that affected DBI may have occurred earlier. Finally, there may have been
no detected differences in cytokine analyses simply because there were too few patients
in any of the group or subgroup analyses to detect these differences in cytokine
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concentrations. This seems most plausible as published studies have generally used at
least twice as many patients in each group. The small number of samples may mask any
potential positive findings in group and subgroup analyses with very low numbers of
subjects. Repeating this analysis with significantly greater numbers may be important
for future studies in this patient population.

5.3.3 Implications of the sCD163 Analysis
There are also several important implications from the sCD163 analysis project.
First, the sCD163 analysis project demonstrated important differences in both plasma and
CSF sCD163 concentrations in aSAH patients compared to the measured concentration in
control patients. This is similar to the previous publication that compared the sCD163
concentrations in aSAH subjects and controls.156 This suggests that there are important
differences in either the rate of CD163 cleavage by ADAM17/TACE to sCD163 between
aSAH and control patients or in the total number of macrophages present in blood or CSF
between aSAH and control patients. In plasma, the sCD163 was non-significantly
decreased in the aSAH patients compared to the control subjects. Future studies should
attempt to evaluate these differences by controlling for changes in macrophage count,
using a ratio of sCD163 concentration and macrophage count. A decrease in both the
sCD163 concentration and the calculated ratio would suggest a decreased production in
sCD163; whereas, a measured decrease in the sCD163 concentration but an increase or
no change in the ratio would suggest that sCD163 was decreased because of a decrease in
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the macrophage count. This novel ratio could also be used to evaluate mechanisms of
increases in the measured sCD163 concentration.

In further analysis of the CSF sCD163 concentration between PBD3 and PBD10,
it is important to note that the sCD163 concentration was already increased significantly
elevated over the controls (approximately 5-fold) at the earliest time point (PBD3) and
peaked between PBD5-7 at approximately 10 times the control concentration. This
suggests that evaluations performed even earlier in the hospital course may provide
additional insights into the time course of sCD163 alterations.

In addition, while there was no significant difference in the sCD163
concentrations in patients with and without DCV or DCI, there were non-significant
differences in patients with and without DCV (decreased in DCV patients), as well as,
those with and without DCI (increased in DCV), starting at PBD3. These findings
suggest that, if sCD163 is involved in the development of DBI as defined in the
mechanistic model, the pathways for DCV and DCI may be separately and differentially
activated and may support sCD163 as one of the “unknown triggers” as described in the
inflammation-mediated model.

It is interesting to also note that the plasma sCD163 concentration in Hp2-2
patients was greater than both the Hp1-1 and Hp1-2 patients at all time points, a finding
that may also support the inflammation-mediated models of DBI as described in Figure 5.
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With data from more patients, this trend may rise to the level of statistical significance.
This is particularly interesting, given that there are significant differences in plasma
sCD163 concentration, with the greatest difference in Hp2-2 patients. Differences in
CSF sCD163 concentrations in patients with regard to Hp phenotypes are more difficult
to interpret from this data; however, the peak sCD163 concentration in Hp2-2 patients is
greater and occurs later (PBD7 vs PBD5) after aSAH in Hp2 patients. It is unclear what,
if any significance, this delayed peak in sCD163 concentration has with regard to clinical
outcomes but may warrant additional research.

Finally, while there were no significant differences in the plasma sCD163
concentrations in the combination of analysis of Hp class and DCV status, the sCD163
concentration in Hp2 patients who did not develop DCV was non-significantly greater
than the other groups. This might, in part, explain why there was no apparent
differences in the sCD163 concentration among patients with and without DCV. The
cause of this finding is unclear and warrants additional evaluation. Differences in CSF
sCD163 concentrations are difficult to assess with no clear patterns to suggest future
directions of research.

In DCI, there were no significant differences in the plasma sCD163
concentrations that were not explained by differences in baseline levels. In CSF, there
was a non-significant increase in the sCD163 in Hp2 patients compared to all other
patients. This may be an important finding, suggesting a statistically significant
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difference may be detected with more patients. These findings should be further
compared to long term clinical outcomes.

5.4 Limitations
5.4.1 Limitations of the UK aSAH biobank
There were several important limitations from the UK aSAH biobank. First, only
25% of all aSAH patients admitted to the University of Kentucky Chandler Medical
Center were enrolled in this study. This was significantly below the predicted
enrollment rate; however, the most common reasons for subject exclusion were related to
patient and disease-specific factors that would have negatively impacted completion of
the research protocols if the exclusion criteria were loosened. Nearly 90% of the
patients were excluded because of just three of these criteria, including “No EVD
placed”, “non-survivable injury” and “no family available for consent”. Estimation of
the rates of these exclusion criteria at the start of this project did not adequately account
for the frequency of these exclusions in aSAH patients hospitalized during the enrollment
period.

Second, during the study period, there was significant variability from year to
year in the number of subjects recruited. In fact, significantly more subjects were
enrolled the first year than the second year (N=20 versus N=5, p<0.001). Unfortunately,
it is not clear whether the enrollment rate in the first year was increased above baseline,
the enrollment rate in the second year was decreased below baseline, or both. In fact, in
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an analysis of the reasons that patients were excluded, there was no one single reason to
explain the significantly reduced enrollment in the second year compared to the first year.
Also, while there was a negative impact in recruitment related to COVID-19 that
impacted the final 4 months of the study period, it is not the primary cause of reduced
recruitment as this trend existed throughout the other 8 months of the year. Recruitment
of patients during the 4-month period at the rate of the previous month would have
increased overall recruitment by just 2 patients.

Third, patient data and biofluid samples were not collected prior to PBD3,
limiting the opportunity to assess changes in cytokines or sCD163 prior to this time point.
The decision to collect biofluid samples starting at PBD3 was made for several reasons,
including patient and family comfort and the impact that this has on subject recruitment.
Anecdotal experience suggests that early discussion of research may cause undue anxiety
in patients and their family that translates to refusal to volunteer for research. By
delaying recruitment and sampling to PBD3, patients and their families were able to see
some early neurologic recovery and to have time to process the consequences of aSAH.
In addition, biofluid sampling was intentionally delayed to PBD3 because the overall
focus of the biobank and subsequent research was to study mechanisms of DBI that start
on PBD3. In the future, collecting data and biofluid samples from subjects before this
time period might, however, provide additional insight into mechanisms of disease and
could be used for in-patient biofluid analyses in future research.
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5.4.2

Limitations of the inflammatory cytokine analysis
There were also several important limitations of the inflammatory cytokine

analysis. First, as has been previously described, clinical data and biofluid samples from
only 24 subjects were available. The low number of subjects likely dramatically
decreased the ability to detect important differences in subgroup analyses. Similarly,
there were also outlier results in many analyses, affecting the data distributions,
necessitating the use of non-parametric statistical tests in essentially all of the analyses.
The effect of these outliers on data distributions were compounded by the relatively low
number of subjects, especially in group and subgroup analyses.

Second, the control subjects were drawn from a large pool of hospitalized patients
rather than healthy research volunteers. This decision was made because lumbar
puncture to obtain CSF in healthy volunteers is not benign nor is it inexpensive. While
the control subjects were screened to remove patients with ventriculitis and meningitis, it
is possible, and perhaps likely, that they had other systemic or neurologic diseases that
necessitated CSF collection and that may have impacted the blood or CSF inflammatory
cytokine concentrations. The use of healthy research volunteers without evidence of
infection or inflammatory diseases as control subjects in future research may improve
research comparisons with aSAH patients.

Third, although the inflammatory cytokines in this study were chosen based on
previously published reports, the analysis of only 3 cytokines limited the ability to detect
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potential changes in other inflammatory pathways. In future analyses, a more complex
panel including more potentially active inflammatory cytokines should, perhaps, be
considered. In addition, the measured concentrations of Il-1β and TNF-α were relatively
low compared to the sensitivity of the assay, limiting the precision of measurement of
small differences that may have existed between group and subgroups of patients. The
use of more sensitive assays for these cytokines may be important in future analyses.

5.4.3

Limitations of the sCD163 analysis
As has been described above, clinical data and biofluid samples from only 25

subjects were available and as was true with the inflammatory cytokine analyses, this low
number of subjects likely decreased the ability to detect important differences in group
and subgroup analyses. The patient with ventriculitis that caused his exclusion in the
inflammatory cytokine analysis was not excluded in this analysis because his sCD163
concentrations were not significantly different from the other study subjects.
Nevertheless, the inclusion of his results in the final analyses may have negatively
impacted the results. In addition, concerns about the impact of sampling, processing and
storage protocols, as well as, sCD163 analysis are similar to the concerns described for
the inflammatory cytokine analysis with the caveat that the UK CCTS BAL had no prior
experience with the sCD163 analysis procedures.

Another potential limitation in the sCD163 analysis project is uncertainty over
whether differences in sCD163 concentrations reflect a key driver of DBI or whether
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these differences reflect injury caused by DBI. Because this is the first study to evaluate
sCD163 in this population, additional research will be needed to clarify the potential
associations that may exist between DBI, Hp phenotypes and sCD163 in aSAH patients.

5.5 Future Directions
5.5.1 Future directions from the UK aSAH biobank project
There are several potential future directions for the UK aSAH biobank project.
First, because overall enrollment in the aSAH research project was too low to support
high-quality research over short time periods, as demonstrated by the previously
described work in the inflammatory cytokine and sCD163 analyses, continued screening
and recruitment of patients to this biobank will remain important for future clinical and
translational research in this population. Although time intensive, enrollment of patients
over a 4-5-year period would be expected to include more than 50 patients, providing
significantly more clinical data and biofluid samples for future research.

Second, in some cases, it may be beneficial to relax or revise exclusion criteria to
increase overall patient enrollment in the biobank. Based on an analysis of the reasons
for subject exclusions, removing the exclusion for subjects who did not receive an EVD
would likely significantly increase the number of patients to recruit. In these patients,
even though CSF samples would not be collected, clinical data and blood samples would
still be collected, processed and stored for future research. In addition, the use of
electronic forms of consent (e-consents) may also increase the likelihood that legally136

authorized representatives are able to provide written documentation of consent in the
event that they are not able to be physically present at the hospital in a timely fashion.

Third, the biobank may significantly benefit from building it into a collaborative
project with other local or regional medical centers to collect data and biofluids from a
larger pool of patients. This would increase the opportunity to recruit patients beyond
the approximately 50 patients per year currently admitted to the UK Chandler Medical
Center. As a secondary benefit, expansion of the single-center biobank may also
improve generalizability of the data collected by including patients from a greater variety
of backgrounds and by minimizing the potential effect that treatment at any single center
may have on the outcomes. In developing these collaborations, it may be possible to,
first, develop partnerships with the other local hospitals, allowing current research
personnel to obtain clinical data and biofluids for processing in a central laboratory at
UK. Further expansion beyond the local community may be desirable and could
capitalize on the pre-existing collaborations with one or more of the UK Center for
Clinical and Translational Science research alliances.

Finally, regardless of biobank expansion opportunities, the biobank should
develop a more formal governance structure. This governance is critical for determining
fair use and compensation of clinical data and biofluid samples by future researchers. In
addition, this governance is important to coordinate regulatory requirements, especially if

137

this project grows into a multicenter biobank. Finally, the governance is important to
formally monitor patient safety, clinical data accuracy, and biofluid sample stability.

5.5.2 Future directions from the inflammatory cytokine analysis project
Because this inflammatory cytokine analysis project was an underpowered, but
ultimately negative study, contradicting the published literature, it will be important to
repeat this study, perhaps with additional samples from the biobank to evaluate the
potential causes of this conflicting data. In addition, as has been discussed elsewhere,
future studies should consider additional cytokines, chemokines and activators of
inflammation that may be involved in DBI after aSAH to more fully develop the
inflammation-mediated model of DBI.

5.5.3 Future directions from the sCD163 analysis project
There are several potential next steps for additional research with the sCD163
analysis project. First, the study should be repeated with more patients and across more
medical centers to test whether the interesting but non-significant findings in this project
might rise to a level of significance with more recruited patients across more medical
centers. These interesting findings include testing differences with regard to DBI, Hp
phenotypes and the combination of Hp phenotypes and DBI.

If, in future studies, these non-significant associations gain more significance,
studies should test whether blood or CSF sCD163 concentration differences reflect
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changes in inflammatory responses. Likewise, future studies should test the association
between blood or CSF sCD163 concentrations and the individual anatomic and
biochemical processes described in Figure 5. These studies will be needed to further
evaluate the inflammation-mediated model of DBI.

Finally, with more patients and medical centers, it might be possible to also test
the associations between blood or CSF sCD163 concentrations and long-term clinical
outcomes, including recovery and disability at PBD90 or beyond. These outcomes are
clinically meaningful and it may be important to establish sCD163 as a target for future
therapeutics or a biochemical method to assess the effectiveness of future therapeutics.

5.6 Conclusion
This chapter detailed the key findings, implications, limitations and future
directions of the development of the UK aSAH biobank, as well as, inflammatory
cytokine analyses and sCD163 analyses to examine mechanisms of DBI after aSAH.
Overall, this work highlights important steps taken to better understand the potential
mechanisms that are triggered by aSAH and that ultimately lead to DBI, neurologic
injury and permanent neurologic disability. Future research should build on this work to
improve patient outcomes in this frequently-devastating disease.
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APPENDICES
APPENDIX 1: UBACC SCORE WORKSHEET
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APPENDIX 2: CASE REPORT FORMS
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APPENDIX 3: HAPTOGLOBIN PHENOTYPE ANALYSIS PROTOCOL

Reagent and Sample Preparation
1. Allow all reagents, controls, and samples to reach room temperature (22-28°C),
including:
a. Concentrated wash buffer stock solution
b. Sample dilution buffer solution (ready to use)
c. Conjugate diluent solution (ready to use)
d. Concentrated HRP-conjugated mAb solution
e. TMB substrate solution (ready to use)
f. Stop solution (ready to use)
g. Positive controls (Hp1-1, Hp1-2, Hp2-2)
2. Prepare wash buffer solution from dilution of 50 ml wash buffer stock in 950 mL
deionized water.
3. Prepare biofluid sample solutions by diluting 15 uL biofluid samples with 135 uL
sample dilution buffer solution.
4. Prepare HRP-conjugated mAb solution by diluting 50 uL of concentrated HRPconjugated solution with 9950 uL of conjugate diluent.

Biofluid Assay Protocol
1. Add 100 uL of blank control sample, positive control samples, and diluted study
samples to appropriate microtiter wells.
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2. Cover plate and incubate for 30 min at room temperature while shaking at
approximately 750 rpm.
3. Wash plate 5 times with prepared wash buffer.
4. Add 100 uL of HRP-conjugated mAb solution to each well.
5. Cover plate and incubate for 30 min at room temperature while shaking at
approximately 750 rpm.
6. Wash plate 5 times with wash buffer.
7. Add 100 uL of TMB substrate to each well.
8. Cover plate and incubate for 30 min at room temperature while shaking at
approximately 750 rpm.
9. Add 100 uL of stop solution (1M H2SO4 solution).
10. Read optical density (OD) at 450 nm in a microtiter plate reader.
11. Calculate the OD upper limit of detection (ULOD) for Hp1-2 phenotype as the
Hp2-2 OD multiplied by 0.6.
12. Interpret results from the O.D. of each sample
a. Hp1-1 = O.D. < 2
b. Hp1-2: O.D between 0.2 and calculated ULOD
c. Hp2-2: OD > calculated ULOD

Test Validation Criteria
1. The O.D. of the blank should be < 0.2.
2. The O.D. of the Hp1-1 positive control should be < 0.2
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3. The O.D of the Hp1-2 positive control should be between 0.2 and the calculated
upper limit of detection for the Hp1-2 phenotype
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APPENDIX 4: CYTOKINE ANALYSIS PROTOCOL
Reagent and Sample Preparation
1. Allow all reagents, controls, and samples to reach room temperature (22-28°C)
2. Prepare calibrator dilutions from calibrator standard using a serial 1:4 dilution
technique with supplied diluent to create calibrator standard samples #1 to #8.
3. Dilute plasma samples (1:2) using supplied diluent.
4. Reconstitute control samples using supplied diluent.
5. Dilute antibody detection samples (1:50) using supplied diluent.
6. Dilute wash buffer (1:20) using deionized water.
7. Dilute read buffer (1:2) using deionized water.

Biofluid Assay Protocol
1. Wash ELISA plate 3 times with 150 uL of wash buffer.
2. Add 50 uL of prepared plasma samples, calibrators, and controls to designated
wells. Seal the plate with an adhesive plate seal and incubate at room
temperature for 2 hours.
3. Wash ELISA plate wells with 150 uL of wash buffer.
4. Add 25 uL of detection antibody solution to each well. Seal the plate with an
adhesive plate seal and incubate at room temperature for 2 hours.
5. Wash ELISA plate wells with 150 uL of wash buffer.
6. Add 150 uL of prepared red buffer to each well.
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7. Analyze ELISA plate on appropriate MSD instrument. Determine target
cytokine concentrations from results of calculated calibration curves.
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APPENDIX 5: sCD163 CONCENTRATION ANALYSIS PROTOCOL

Reagent and Sample Preparation
1. Allow all reagents, controls, and samples to reach room temperature (22-28°C)
2. Prepare wash buffer solution from dilution of 20 mL of wash buffer in 480 mL of
deionized water.
3. Prepare calibrator diluent solution from dilution of 20 mL of calibrator diluent in
20 mL of deionized water.
4. Prepare serial calibrator dilutions from 300 uL calibrator standard using a serial
1:2 dilution technique with 300 uL of deionized water to create calibrator standard
samples #1 to #8 with concentrations ranging from 200 ng/mL to 1.56 mg/mL.
5. Prepare substrate solution by mixing color reagents A and B together (1:1) within
15 minutes of use.
6. Prepare biofluid samples (plasma or CSF) using a 1:4 dilution technique with 15
uL of biofluid and 45 uL of prepared calibrator diluent.

Biofluid Assay Protocol
1. Add 100 uL of calibrator diluent to appropriate microtiter wells.
2. Add 50 uL of prepared biofluid samples, calibrators, or controls to designated
wells. Seal the plate with an adhesive plate seal and incubate at room
temperature for 2 hours.
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3. Aspirate liquid from each well then wash each well with 400 uL of wash buffer.
Perform this step 4 times.
4. Add 200 uL of detection antibody solution to each well. Seal the plate with an
adhesive plate seal and incubate at room temperature for 2 hours.
5. Aspirate liquid from each well then wash each well with 400 uL of wash buffer.
Perform this step 4 times.
6. Add 200 uL of substrate solution to each well. Incubate for 30 minutes at room
temperature. Protect from light.
7. Add 50 uL of stop solution to each well.
8. Determine the optical density of each well using a microplate reader set to 450 nm
with wavelength correction set to 540nm.
9. Create a standard curve using a log-log curve-fit from the calibrator and control
samples results.
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